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Abstract
Oxidative metabolism is required to produce adequate energy to sustain human life. A primary
example of deteriorating oxidative capacity is seen in the cardiac musculature during chronic
heart failure. This suggests that by improving oxidative potential, chronic heart disease could be
mitigated and one approach to accomplish this may be through targeting the mt-mRNA
translation system. Purpose: This investigation’s purpose was to characterize disruptions in mtmRNA translation machinery in multiple forms of cardiomyopathy and to determine if
mitochondrial mRNA translation initiation factor (mtIF2) is necessary to maintain oxidative
capacity in cardiomyocytes. Methods Using a combination of animal and cell culture
experiments, we first analyzed the oxidative detriments of the myocardium using an LLC tumor
implantation model and followed by assessing how antioxidant protection against LLCconditioned culture media. Additionally, we used a model of concurrent aging and high fat-diet
induced cardiac hypertrophy. After identifying mtIF2 as a potential contributor to oxidative
detriments in the heart, we used genetic alterations of H9c2 cardiomyocytes to characterize its
necessity. Analyses performed in animal and culture experiments include optical metabolic
imaging, immunoblot of mitochondrial quality controllers, bioenergetics flux analysis and
hypoxic resistance, Results: LLC-implanted animal hearts demonstrated ~15% lower optical
redox ratio (FAD/FAD+NADH), a marker for greater glycolytic reliance compared to controls.
mt-mRNA translation machinery was unchanged between groups relative to amount of
mitochondria. Mitochondrial DNA-encoded CytB was ~30% lower in LLC hearts suggesting
impairments in outcomes of mitochondrial mRNA translation. Aged mouse hearts were larger
and contained less mtIF2 protein alongside reduced content of CytB. Reducing the content of
mtIF2 is associated with reduced oxidative characteristics such as OXPHOS complex I and IV

content, optical redox ratio, oxygen consumption, and viability following hypoxia. Conclusion:
In conclusion, the research investigations presented within this dissertation are the first to
establish mitochondrial mRNA translation as a process that is dysregulated during
cardiometablic disease and as a potential therapeutic target to enhance oxidative characteristics
of the myocardium. mtIF2 presents as a key regulator for the process of mt-mRNA translation
and is necessary for maintain oxidative capacity in cardiac muscle.
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Chapter 1 – Introduction
Significance
Total CVD is the most common cause of death worldwide (>31% of all deaths) 1. This
includes many of the costliest diseases in the developed world such as heart failure, myocardial
infarction, coronary artery disease, and stroke1,2. Over a century of research has contributed to
the fields of heart diseases, biochemistry and oxidative metabolism, including the discovery and
characterization of the organelle responsible for energy production within the heart – the
mitochondrion3,4. Only recently have researchers been able to show the interconnectedness
between energy production allowing the heart to pump blood and how it can lead to heart
disease5. Heart disease, in turn, leads to degeneration of mitochondria through free radicals
further damaging the energy production machinery and allowing the disease to progress 6.
Heart disease – Cardiomyopathy is clinically recognized by symptoms of congestive
heart failure, reduced left ventricular ejection fraction, enlarged ventricular chamber walls,
dilated left ventricle, or poor cardiopulmonary exercise test performance 1. These symptoms
occur when the contractile muscle cells of the heart become stiff as a result of buildup of noncontractile tissue such as scar tissue and collagen. When the heart develops this buildup of
fibrotic tissue, it is less efficient at pumping blood throughout the body and requires greater force
to produce the same cardiac output. Furthermore, in order to compensate for this inefficiency, the
cardiac cells contract more frequently and thus consume and metabolize more energy. Metabolic
pressure alters the molecular behaviors of cardiac energy metabolism.
Perinatal cardiomyocytes demonstrate a surprising reliance on glycolytic metabolism. At
birth, a shift towards oxidative metabolism of fatty acids occurs concomitant with expansion of
the number of mitochondria within the cardiomyocyte7. During healthy, adult myocardial
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metabolism, up to 90% of the energy for contraction is generated through β-oxidation of fatty
acids8. As heart disease progresses, the cardiomyocyte cannot provide the necessary energy
through fatty acids and begins to rely on glycolytic metabolism9. This temporally shifts the cell
back towards this perinatal state10. Current research attempts to mitigate heart disease
progression by improving the reliance on fatty acid substrates for energy metabolism and this
seems to contribute to decreased mortality. The location of fatty acid metabolism – the
mitochondrion – seems to play a key role in this metabolic shift. Importantly, the mitochondria
also generate many of the signals for the cell to begin apoptosis or shift metabolic states. For this
reason, understanding how the mitochondria function during heart disease progression can
improve understanding for approaches to treat the disease9.
Mitochondria – Greater than 30% of the volume of cardiomyocytes is attributed to
mitochondria. These organelles turnover roughly the body’s weight in ATP each day through
oxidative metabolism11. This process is highly efficient and capable of operating in vivo at 8090% of the enzymatically defined maximal capacity11,12. Within the mitochondria are necessary
enzymes for the processes of β-oxidation, the TCA cycle, redox handling, mtDNA, proteins to
allow mtDNA expression as well as numerous other regulatory and functional processes.
Evolution has maintained the necessity to use the mitochondria to produce energy efficiently but
has done so by transferring >99.5% of the mitochondrial genome to nuclear DNA13–15. The fact
that mammalian mitochondria still contain 13 protein-encoding genes that are vital for oxidative
metabolism indicates a biological necessity to maintain a separate and energetically expensive
set of mtDNA along with hundreds of associated proteins. Each of the proteins encoded by
mtDNA are core subunits of the oxidative phosphorylation system complexes 16. Mutations in
these genes are associated with system-wide diseases that stem from poor energy production15.
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Unfortunately, mtDNA is highly susceptible to mutation because of 1) lack of dedicated mtDNA
repair machinery, 2) no sexual recombination upon replication, 3) an incomplete mitochondrial
degradation that causes potential replication of damaged mtDNA and 4) proximity to the electron
transfer machinery17. The latter is of importance because of the potential for improper electron
transfer to generate mutagenic free radicals.
Electron transport and ROS – Peter Mitchell’s chemiosmotic theory explains the
movement of electrons through the ETS on the inner mitochondrial membrane to generate an
electrochemical gradient, Δψm, used to produce ATP18,19. The electron transfer proteins
(Complexes I-IV) are highly complex and utilize an elaborate series of oxidation/reduction
reactions to transfer electrons through a number of electron carriers 20. These electron carriers
assist in generation of Δψm and allow complex V (ATP synthase) to use this potential to generate
ATP21,22. This electron transport process is susceptible to producing harmful byproducts in the
form of superoxide O2 - which rapidly generates other forms of reactive oxygen species
(ROS)15,23. Under healthy metabolic conditions, the cell (and mitochondria) are able to neutralize
these free radicals by using a combination of dismutase and catalase enzymes turning the
superoxide into harmless water24. However, under conditions of impaired metabolism or
oxidative stress, the ETS can generate enormous amounts of superoxide which exceed the
capabilities of the ROS mitigation system of the cell. These free radicals induce serious damage
to cellular components including lipid peroxidation of biomembranes, protein oxidation forming
aggregates, advanced glycation end products, cleaved RNAs and greater than 25 known
alterations to DNA24–26. The mutations in DNA include base modifications that prevent
transcription or replication, alterations that generate SNPs, and single strand breaks from
deoxyribose scission26–32. Because of the limited machinery for mtDNA repair, these mutations
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accumulate and cause severe detriments to oxidative capabilities leading to even further ROS
production and a self-propagating cycle ensues. Many of the ETS core proteins are encoded by
mtDNA and synthesized within the matrix by mt-mRNA translation machinery33.
mt-mRNA translation – Expression of mtDNA-encoded genes requires a discreet set of
translation machinery within the mitochondrial matrix including mitoribosomes, mt-tRNAs, and
a specialized set of proteins controlling the translation processes33–35. These proteins include
initiation factors (mtIFs), elongation factors (mtEFs), and translation activators that govern each
step of the mt-mRNA translation process. Because translation initiation is a committal step and
polypeptide elongation is extremely energetically expensive (2-4 ATP/peptide), these translation
factors are important controllers of the processes36. Specifically, mammalian mtIF2 has taken on
the historical functions of both bacterial and eukaryotic IFs-1and -2 (binding of 28S
mitoribosomal SSU and GTP-dependent association of fMet-tRNA with SSU P-site,
respectively)37. mtIF3 contains a tether-like linker region with binding activity of both
mitoribosomal subunits allowing formation of the complete initiation complex38. mtEFTu
provides GTPase activity for peptide bond formation between multiple aa-tRNAs, and TACO is
a translational activator which assists in colocalization of each piece of the translation system to
the mitochondrial membrane where the protein will be inserted 39,40. The tightly regulated process
of mt-mRNA translation requires adequate maintenance of this machinery and is subject to
alterations during metabolic stressors such as cardiomyopathies41.
Previous Research – Decades of investigation have identified metabolic dysfunctions
including mitochondrial detriments in the pathology of heart disease 9,42,43. A transition away
from fatty acid metabolism and increased oxidative demand to maintain cardiac output result in
stress on key ETC complexes, greater reduction of electron carriers, and thus elevated rates of
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ROS production44–4748. Previous research demonstrates that elevated ROS production enhances
mtDNA mutations, causes early onset heart failure, and decreases lifespan17,26,49–51. However, the
opposite holds true that enhancing ROS mitigation can limit mtDNA mutations and extend
lifespan in rodents52. Mutations in key protein controllers of mt-mRNA translation result in
altered ETC capacity and greater ROS production15. Furthermore, my previous research suggests
mt-mRNA translation machinery as being sensitive to change by metabolic stimuli such as
obesity or exercise (Figure 1)41,53. This suggests that mt-mRNA translation machinery may be
dysregulated during cardiomyopathy. One approach to control heart disease may be to limit
oxidative stress in the mitochondria by controlling the mt-mRNA translation/electron transport
complex/ROS production circuit 6. In order to assess this approach to combat heart disease, we
must first identify how mt-mRNA translation machinery affects oxidative capacity and ROS
production and if the mt-mRNA translation machinery is required for oxidative metabolism
and is disrupted in myocardial pathologies. Experiments to test this central hypothesis will be
designed according to these specific aims.
Innovation
Cancer is one of the deadliest diseases in the world second only to heart disease2. These
experiments will examine an untouched area controlling oxidative metabolism – mt-mRNA
translation. We will experimentally define the role of mt-mRNA translation in maintaining
oxidative capacity and mitigating ROS production. In doing so, we will assess oxidative
characteristics in two unique and understudied models of heart disease: cardiac hypertrophy
resulting from the combination of aging-induced sarcopenia coupled with high fat diet-induced
obesity as well as cardiac atrophy seen commonly as a side effect of cancer wasting syndromes.
The approaches that we will use to assess oxidative capacity and redox states of the
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cardiomyocytes are highly innovative because they have not been used previously, in this
combination, to assess the oxidative characteristics of cardiac cells during these chronic disease
states and the most appropriate in testing the central hypothesis.
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Chapter 2 - Review of Literature
Total CVD is the most common cause of death worldwide (>31% of all deaths). This
includes many of the costliest diseases in the developed world such as HF, MI, CAD, and stroke.
Over a century of research has contributed to the field of heart diseases, biochemistry and
oxidative metabolism, followed by the discovery and characterization of the organelles
responsible for energy production within the heart. Only recently have researches been able to
show the interconnectedness between energy production to allow the heart to pump blood and
how it can lead to heart disease. Heart disease, in turn, causes degeneration of mitochondria
through free radicals further damaging the energy production machinery and causing the disease
to get worse. This review will define the current definitions and understandings over the areas of
cardiovascular disease, cardiac bioenergetics, mitochondria, electron transport, and reactive
oxygen species. These will include up-to-date evidence on the current knowledge in each
respective field. In whole, this review will attempt to show how each of these topics can be
formed into a working theory on the contribution of mt-mRNA translation in maintaining
cellular oxidative metabolism. This will culminate in the development of a research proposal
entitled: Mitochondrial mRNA translation is required for maintenance of oxidative
capacity.
1.Cardiovascular Disease
1.1.Definitions As defined by the American Heart Association, total cardiovascular disease
(CVD) includes rheumatic heart disease, hypertensive diseases, ischemic heart diseases,
pulmonary heart diseases, pulmonary circulation diseases, other forms of heart diseases,
cerebrovascular diseases, atherosclerosis, diseases of the arteries, arterioles, capillaries, veins,
lymphatics not classified elsewhere, unspecified disorders of the circulatory system and
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congenital cardiovascular defects. Of those diseases included in total CVDs, coronary heart
disease (CHD) is the most prevalent followed by heart failure. CHD includes acute myocardial
infarction (MI), angina pectoralis (chest pain, AP) and heart failure (HF). The Center for Disease
Control and Prevention (CDC) helps to outline defining characteristics of these specific
conditions. HF, or congestive HF, results from the inability for the heart to provide adequate
blood supply to other organs in the body. Conversely, MI results from the hearts inability to
provide itself with sufficient blood supply due, usually, the blockage of coronary blood flow. An
underlying cause and effect of many of these heart diseases is cardiomyopathy which is when the
heart becomes enlarged and stiff decreasing the effectiveness of the heart pumping.
1.2.Statistics Because of the overlapping nature of many different forms of CVD and CHD,
many of the statistics cannot be added together to derive a meaningful total.
1.2.1.Total CVD Total cardiovascular disease (CVD) includes rheumatic heart disease,
hypertensive diseases, ischemic heart diseases, pulmonary heart diseases, pulmonary circulation
diseases, other forms of heart diseases, cerebrovascular diseases, atherosclerosis, diseases of the
arteries, arterioles, capillaries, veins, lymphatics not classified elsewhere, unspecified disorders
of the circulatory system and congenital cardiovascular defects.
1.2.1.1.Morbidity and Mortality Greater than 85 million Americans (~26% of the population)
currently have at least one form of CVD. CVD has been the primary underlying condition of
more deaths every year for more than a century in the United States. For the most recent annual
records, CVD caused 30.8% (801,000) of deaths in the United States and CVD was mentioned in
54% (1,402,000) of all death records. For adults >65 years of age, CVD was the leading cause of
death regardless of sex and ethnicity. Greater than 155,000 Americans died before age 65 due to
CVD. Greater than 1 in 3 deaths that occurred because of CVD happened before average life
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expectancy was reached (78.8 years). On a global scale, CVD is still the leading cause of death
and represents ~1/3 deaths worldwide1. Worldwide, the differences in mortality are seen between
men and women but death rates are much greater in low to middle income countries2.
1.2.1.2.Costs The estimated total costs of CVD in the United States is currently $317 billion
(USD). Increases in CVD costs are projected through the year 2030 for the United States and
will near $1,000 billion3. Similarly, an increase of nearly three times the current amount is
projected for worldwide costs associated with CVD from $860 billion to > $2,000 billion by
2030.
1.2.2.Coronary Heart Disease Coronary heart disease includes acute MI, angina pectoralis and
HF.
1.2.2.1.Morbidity and Mortality Total prevalence of CHD among men and women in the US is
6.2% of the population over 20 years aged. Because of the frequency of ‘silent’ MIs (that is MI
where ischemic damage has occurred with no symptoms), there is some difficulty in estimating
incidence of MI. Annual estimate of MIs in the United States is 550,000 new attacks and
200,000 recurrent attacks. Assuming ~21% of first and recurrent attacks are silent, Americans
will suffer ~660,000 first time heart attacks and ~305,000 will suffer recurrent attacks. Men and
women suffer CHD at different rates. Average age for first MI in men is 65.1 years while
average age for women is 72.0 years. The overall incidence lags behind in women by about 10
years but for serious, life threatening or hospitalizing events such as MI or sudden death, women
lag behind by ~20 years. CHD was the underlying cause of death in ~1 in 7 (370,000) American
deaths. Specifically, MI contributed to ~1/3 of all CHD deaths (117,000). The estimated average
years of life lost due to MI death is ~17 years.
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1.2.2.2.Costs Average direct and indirect annual costs due to CHD in the United States is ~$210
billion. MI and CHD were 2 of the top 10 most expensive hospital discharge statements (~$22
billion combined). Average medical costs due to MI and CHD are expected to double in the next
10 years to nearly $500 billion.
1.2.3.Cardiomyopathy and heart failure Cardiomyopathy occurs when the striated muscle of
the heart becomes stiff due to buildup of scar tissue or non-functional contractile tissue and
causes the heart to become less functional at circulating blood to the organs of the body.
Throughout the world, heart failure was most highly associated with hypertension4.
1.2.3.1.Morbidity and mortality Cardiomyopathy is responsible for 23,000 deaths of
Americans over the most recent year’s estimates and is mentioned in almost 50.000 of the
records of all-cause mortality cases. Hypertrophic cardiomyopathy is the most common heart
defect and occurs in ~500,000 Americans while most are not aware of its prescience5. In the last
two decades, the global death rate attributed to cardiomyopathy has increased substantially
(41%) to >403,000 deaths. Estimated projections show that HF will increase by almost 50% in
the next decale to over 8,000,000 people over the age of 18 6. Over ¾ of cases of heart failure
have antecedent hypertension. After age 40, men and women both have the same risk for
developing HF at 1 in 5 adults. One in nine deaths mentions HF on the death certificate7.
Unbeffiting disease of the Western society, HF is common in sub-Saharan Africa at 44% of
patients with CVD but occurs at a younger age8. It is worth noting that heart failure with
conserved ejection fraction (EF) is associated with a greater survival rate over fifteen years 9.
1.2.3.2.Costs In the year 2012, HF attributed to an estimated cost of ~$31 billion6. Projections
predict that heart failure will exceed $70 billion in 2012. This results in an estimated cost $250
for every American adult.
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1.3.Health Behaviors and other risk factors Risk of one developing total CVD is tightly
connected to how a patient is characterized based on the AHA’s newly created list of 7 metrics.
These include both lifestyle health behaviors (diet quality, physical activity levels, smoking,
body composition) and health measurements/biomarkers (Total cholesterols, blood pressure,
blood glucose). Each of these can be treated as if there exists a spectrum of cardiovascular health
of ideal, intermediate, or poor health. Additionally, many of these 7 metrics can independently
contribute to disease states that are additional risk factors for CVD (i.e. diabetes mellitus,
metabolic syndrome).
1.3.1.Smoking/Tobacco Use According to reports by the Surgeon General, smoking is a major
risk factor for total CVD10. Smoking as a risk behavior is considered as an ideal behavior if one
has never smoked or has quit smoking >12months ago. Additionally, risks of CHD, acute MI and
stroke is increased for those who work or live in an environment with secondhand smoke. There
is not enough evidence yet to determine a risk of electronic nicotine delivery systems such as ecigarettes on CVD risk11.
1.3.2.Physical Inactivity Getting too little physical activity is a major risk factor for CVD12. One
in 3 children and less than half of adults meet the requisite physical activity criteria. Although
distinct from physical activity, measures of cardiorespiratory health is a stronger predictor of
CVD risk13. In 2014, just 21.4% of adults met federal guidelines for adequate physical activity.
Association of physical activity and decreasing metabolic risks is maintained regardless of
weight loss from the physical activity14.
1.3.3.Nutrition Multiple factors contribute to the contribution of dietary intake to CVD risk.
Specifically, a DASH-type diet (dietary approach to stop hypertension) is recommended. These
guidelines include increasing whole grains (>3 servings/day), increasing fruit (>2 servings/day),
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increasing non-starchy vegetables (>2.5 servings/day), increasing fish and shellfish (>2
servings/week), increasing nut and seeds (>4 servings/week), decreasing red meat, decreasing
sugar-sweetened beverages, decreasing sweets and bakery desserts, decreasing saturated fats,
increasing unsaturated fat and omega 3-fatty acids, increasing fiber, decreasing sodium, and
increasing potassium intake. Improving healthy eating among the population is the most costeffective approach to decreasing risk of CVD compared to smoking cessation, statin therapy, and
lifestyle advice15.
1.3.4.Body Composition Maintaining a BMI ≤25kg/m2 is one of the 7 components of
maintaining ideal cardiovascular health. Being overweight (25kg/m2 ≥ BMI ≥ 29.9kg/m2) or
obese (BMI ≥ 30kg/m2) is considered a major risk factor for total CVD including CHD, AF,
CHF, stroke, and venous embolism. Based on recent NHANES data, 69% of American adults are
overweight or obese. Obese individuals pay ~$1,500 more for health care costs than normalweight individuals including 50% more inpatient costs, ~25% more outpatient costs, and ~80%
more on prescription drugs16. Strong evidence exists for bariatric surgery among patients with a
BMI ≥ 40kg/m2 though few clinical trials exist. Bariatric surgery can cause substantial weight
loss, remission of DM, hypertension and dyslipidemia and reduce total medical expenses by
~$10,000 within 5 years17.
1.3.5.Family History First degree relatives share their genetic variation much more than a
randomly selected individual. Likewise, those with similar racial/ethnic backgrounds tend to
demonstrate similar genetic variations within the specific population. This contributes to
complex genetic factors involved in CVD risk that might be ascertained via family history of
CVD. Risk of premature heart attack, acute MI, AP, angioplasty, bypass surgery, CHD, aortic
fibrosis, stroke, PAD, and venous embolism are all much higher in those who have a first degree
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relative with history of the respective CVD. Recent consortia have produced genetic studies of
CAD associated with specific genetic loci. While low odds ratios are seen, individuals may hold
up to two alleles of a single gene and multiple genes involved in CVD risk18.
1.3.6.Blood Cholesterols High cholesterol has been considered a major risk for total CVD with
ideal levels for cardiovascular health being < 200mg/dL total cholesterol for adults. Less that
50% of adults currently meet this ideal criterion.
1.3.7.Blood Pressure High blood pressure is a major risk factor for CVD and stroke. The ideal
blood pressure considered ideal for cardiovascular health is <120mmHg SBP and <80mmHg
DBP. ~40% of American adults currently meet this standard. Over 400,000 deaths per year
mention HBP in deaths. When compared with out causes of CVD deaths such as dietary, lifestyle
and metabolic risk, HBP is the leading cause of death among women and the second-leading
cause among men (behind smoking19.
1.3.8.Diabetes Mellitus Untreated fasting blood glucose level of <100mg/dL is a component of
ideal cardiovascular health. DM or uncontrolled hyperglucosemia is present in >50% of adults
and is a major risk factor for CVD including CHD, stroke, PAD, HF, and AF.
1.3.9.Metabolic Syndrome Combinations of cardiometabolic risks can be categorized as
metabolic syndrome and can be beneficial in clinical and patient communications involving the
nature and etiology of the diseases. Fasting glucose, dyslipidemia, adiposity, and blood pressure
above ideal levels, when taken into combination, characterize metabolic syndrome.
1.3.10.Chronic Kidney Disease End-stage renal disease (patients undergoing dialysis or
receiving kidney transplantation) increases risk for CVD. While less common, renal disease is
associated with DM and HBP due to altered filtration through the kidney tubules.
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1.4.Functional Assessment of Heart Disease To understand the underlying etiology of heart
diseases, it is valuable to understand how a patient’s heart is functioning. Electrical assessment,
imaging modalities, circulating biomarkers and physical activity capacity (measured via CPET)
are all ways in which one can assess various factors influencing cardiac health. The primary goal
of these functional assessments is to determine the etiology of exertional fatigue and dyspnea 20.
CPET can determine where in the cardiopulmonary system is lacking while echocardiography is
able to visually image the specific function of the heart that may be at fault. The most powerful
tool in this regard is echocardiography due to its ability to assess systolic and diastolic function
of ventricles as well as other issues21–23.
1.4.1.Echocardiography While still undergoing refinement in the 1970s and 1980s, utilization
of echocardiography to assess cardiac architecture has become an increasingly powerful tool for
visualizing heart function. Initially, even with low quality sensors, much debate surrounded
calculations that were viable, simple, and specific in detecting LVEF21,24. Many of these
approaches were not sensitive in comparison to calculations that became available with improved
piezoelectric crystals23. These and other advances would eventually lead to accurate evaluation
of pulmonary hypertension, thrombus, valve dysfunction, ischemia, and viability in heart
failure25–27. Multiple clear markers of heart failure are evident through echocardiograph
assessment. Enlargement of the heart is highly associated with mortality and an important
predictor of clinical outcomes in heart failure28–32. A stronger determinant of cardiac health,
rather than chamber dimensions, is LVEF33.
1.4.2.Cardiopulmonary exercise testing Cardiopulmonary exercise testing is quickly becoming
a clinically relevant functional assessment predictive of HF prognosis 34. Recently, the AHA has
even suggested the cardiorespiratory fitness should be assessed clinically as a vital sign35,36. This
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non-invasive testing process can determine if insufficiency in exercise capacity is due to
myocardial/circulatory or gas exchange abnormalities20,37. Other testing methods have been used
as well to predict functional capacity and mortality of those with heart disease including overall
cardiorespiratory fitness38, heart rate recovery after activity39, a non-exercise testing method40,
assessment of 6-minute walk test41, among other functional measurements42.
1.5.Molecular alterations during heart disease A multitude of alterations are seen at the
cellular and molecular level of cardiac cells including alteration in contractile tissues and a
changing metabolic profile of the existing tissue. The common representation of the myocardium
is a machine that is able to convert potential chemical energy into kinetic mechanical energy in
the form of a hydraulic pump43. In the case of ischemic heart damage, alterations in cellular and
metabolic components is due to apoptosis stimulated by hypoxia and a lack of energy
substrate44,45. However, critics suggest this creates a circular argument in that a reduction in
contractile components might propagate metabolic insufficiencies and that the true cause may be
caused by transient intramyocardial bioenergetic stressors43. To demonstrate how cellular
bioenergetics plays a crucial part in heart disease (similar to hemodynamic alterations), a review
of the bioenergetic processes involved in cardiac disease and the molecular and cellular
processes follows.
2.Cardiac Energy Metabolism The heart contributes less than 0.5% to total body weight but
nearly 10% to total energy consumption through ATP 46 yet the amount of ATP stored in the
myocardium is only sufficient to support a few heart beats47. Around 90% of the ATP in cardiac
muscle is utilized in the contraction-relaxation cycle – both active processes. Both the release of
actin from myosin during contraction/systole48 and cytoplasmic sequestration of calcium during
relaxation/diastole requires significant amounts of ATP 49. Between 60 and 70% of ATP
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hydrolysis is used in contraction which the remaining 30-40% is used for sarcoplasmic Ca2+
uptake50,51. maintain such a high metabolic turnover rate, cardiac cells contain the greatest
content of mitochondria compared to any other tissue in the body at nearly 30% of cell volume52.
In vivo working hearts are able to produce ATP at 80-90% of the mitochondrial OXPHOS
capacity53. To The cardiomyocyte has also developed a sensitive array of cytoplasmic sensors
(Ca2+, ADP, Pi) that act as a control network over mitochondrial energy conversion to maintain
myofibrillar potential energy homeostasis54. Mitochondria present as an integral part of cardiac
energy metabolism allowing for : 1) utilization of carbon substrates, 2) the generation of high
energy ATP through the electron transport system, and 3) the translocation of the ATP to the
myofibrils to be used for contractile work45.
2.1.Carbon substrate utilization Mitochondrial oxidative phosphorylation is fueled by
electrons generated when carbon energy substrates are oxidized to form reduced NADH and
FADH2 primarily in fatty acid β-oxidation, the TCA cycle, and in small part from pyruvate
dehydrogenase and glycolysis reactions55. Carbon fuel sources for ATP generation are
stoichiometrically linked to the contractile power produced by the myocardium. In a healthy,
oxygenated heart, the primary carbon substrate of the TCA cycle, Acetyl-CoA, is generated
predominantly by fatty acid β-oxidation over carbohydrates from glycolysis/lactate metabolism
in a range from 60%/40% to 90%/10% (fatty acid/pyruvate) 56–58.
2.1.1.Glycolytic substrates The myocardium is a net consumer of lactate even under maximal
workload except for cases of ischemia59 and insulin dependent diabetics60. The glycolytic
substrates of the heart are circulating glucose or intracellular glycogen stores. Extracellular
glucose is endocytosed in a GLUT-4 (and partly GLUT-1) dependent manner indicated
susceptibility to contraction, AMPK, and insulin stimulation61. Internal glycogen stores can be
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converted to G6P for glycolysis though cardiac glycogen stores are relatively small and turnover
rapidly62. The end of the glycolytic process produces pyruvate which has three possible fates:
becoming lactate, acetyl-CoA, or anaplerosis. Glycolytic reactions and pyruvate utilization is
inversely related to plasma FFA levels as suggested by the Randle cycle or glucose-fatty acid
cycle63,64.
2.1.2.Β-oxidation substrate While glycolysis substrates are either stored within the cell
(glycogen) or absorbed in response to insulin, contraction, or inadequate energy (blood glucose),
fatty acids are not stored and must be taken up continually. The uptake of fatty acids is
dependent on the concentration of plasma nonesterified free fatty acids which is highly variable
and sensitive to both acute and chronic metabolic stimuli65–67. Fatty acids are extremely
hydrophobic and as such require close association with carrier or transport proteins to move
freely (i.e. bound to coenzyme A or covalently as triglycerides). The uptake of fatty acid by the
cell also requires specialized transport proteins (fatty acyl translocases, fatty acyl binding
proteins) or passive diffusion from an albumin bound form in the plasma to a cellular carrier 68.
Once inside the cell, fatty acids are generally esterified into a fatty acyl-CoA which cannot be
directly transported through the mitochondrial membranes to the matrix where β-oxidation can
occur69. A series of acyltranslocases allow the passage of the fatty acyl-CoA from the cytoplasm
to the matrix -- primarily controlled through carnitine palmitoyltransferase-I. Carnitine
palmitoyltransferase-I is the key regulator of fatty acid import into the mitochondrion and is
negatively regulated by malonyl-CoA which is generated by acetyl-CoA carboxylase66. Once
inside the mitochondrial matrix, the fatty acyl is oxidized through β-oxidation which cleaves off
consecutive two-carbon acetyl-CoA molecules producing reduced NADH and FADH266,67.
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2.1.3.Ketone bodies It should be noted that ketone bodies such as β-hydroxybuterate and
acetoacetate can be utilized for energy by the myocardium. This only occurs when plasma
concentration reaches levels only seen during uncontrolled diabetes or starvation and is a very
minor substrate70,71.
2.2.ATP generation through the electron transport system Electron transport will be
addressed in detail in section 4 but, briefly, carbon metabolites are utilized in glycolysis, the
TCA cycle, and β-oxidation to generate reduced electron carriers NADH and FADH2. These
electron donors are used in a series of redox reactions along each of four mitochondrial inner
membrane complexes to generate an electrochemical gradient between the mitochondrial
membranes. This proton motive force is utilized by F0/F1 ATP synthase to generate high energy
ATP from ADP and Pi72.
2.3.Translocation of ATP to myofibrils for contraction ATP molecules are generated by the
ATP synthase within the mitochondrial matrix but must be transferred to the myofibrils where
the majority of energy is used within the myocardium50,51. ATP can be easily transported outside
of the mitochondrion by Adenine Nucleotide Translocase where the high energy phosphate is
temporarily stored with a creatine molecule by the creatine kinase reaction. This allows high
energy phosphates to be generated within the mitochondrion but then transported and utilized at
the sarcoplasmic reticulum and myofibrils for the processes of contraction and relaxation. Recent
studies have shown how the speed of this movement is far too rapid for simple diffusion through
the cell and instead use the mitochondria as a reticulum. This allows the generation of the proton
motive gradient in one location (presumably near the source of carbon substrates) and use the
energy to form ATP at a distant part of the mitochondrion (near the myofibrils/sacroplamic
reticulum)55,73. Fragmentation of the mitochondria may lead to detriments in the distance the
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mitochondrial reticulum can transfer energy (see section 3.1.2). This mitochondrial reticulum is a
highly regulated and dynamic concept that is heavily involved in cardiac health and disease.
3.The Mitochondrion Cardiac mitochondria are organized in such a way as to allow energy
production near the cellular locale in which the energy will be used -- near the SR
(subsarcolemmal), nucleus (perinuclear), or contractile apparatus (intramyofibrillar)74.
Mitochondria are extremely dynamic organelles which were investigated as soon as the early
1900’s because they’re constantly being combined, separated, expanded, or destroyed75. Each of
these processes are highly regulated and contribute to the structural and functional integrity of
the organelle for optimal energy production76. This section will briefly detail each of these
processes with particular interest in how they are affected in heart disease. It will then focus on
mtDNA and the processes that allow mtDNA to facilitate proper energy production in the heart.
3.1.Mitochondria in brief The mitochondria exist as a discreet organelle with symbiotic origins
that now acts as the primary source of oxidative energy production in eukaryotic cells 77. The
mitochondria contain an outer membrane sectioning the organelle from other cellular
components and an inner membrane that form cristae to increase surface area and form a discreet
internal matrix. Within the mitochondrial matrix are the necessary enzymes for the processes of
β-oxidation, the TCA cycle reactions, redox handling proteins, mtDNA and proteins to allow
mtDNA transcription and translation as well as numerous other regulatory and functional
processes. Integrated within the inner membrane are transporter proteins and the ETC complexes
which use electron donors (NADH and FADH2) in a series of redox reactions to move protons
from the mitochondrial matrix to the intermembrane space. This generates an electrochemical
gradient or a proton motive force that is utilized by the F0/F1 ATP synthase to create energy.
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3.1.1.Fusion of mitochondria Within a cell, multiple mitochondria may combine by joining
their inner and outer mitochondrial membranes (IMM and OMM, respectively). This allows
more efficient and homogenous sharing of components of the matrix and combining the
electrochemical gradient within the intermembrane space78. Mitochondrial fusion proteins can
contribute to larger, more stable and efficient mitochondria and thus energy production – vital to
maintain oxidative metabolic potential during pathologies associated with heart disease. The
combination on the membranes is primarily controlled by the protein mitofusin-1, mitofusin-2
(both for OMM fusion), and optic-atrophy-1 (for IMM fusion)79,80. The expression levels of
these proteins is sufficient to control the process of mitochondrial fusion but can be further
modified through post-translational modifications including phosphorylation and
ubiquitylation/degradation81. Mitochondrial fusion proteins seem to be particularly susceptible to
ROS during reperfusion injury, are downregulated in diabetes and can dictate the preference for
metabolic substrate82–84.
3.1.2.Fission of mitochondria Mitochondrial fission is required to maintain a balance with
mitochondrial fusion to maintain shape, size, number, and homogeneity of mitochondria
populations85. The primary controller of mitochondrial fission is dynamin-related protein 1
(DRP-1). DRP-1 is a GTPase (similar to each of the fusion proteins) that undergoes the catalytic
activity to break apart the IMM and OMM of separating mitochondria. A key difference lies in
that DRP-1 does not contain a mitochondrial membrane anchoring sequence and must be
recruited from the cytosol to the OMM and bound to one of a few assembly proteins. These
OMM proteins are key to recruitment of DRP-1 and aid in the process of mitochondrial fission:
mitochondrial fission protein, mitochondrial fission factor, and mitochondrial dynamics proteins
49 and 5186. Calcium induces the translocation of DRP-1 to the OMM and is seen prominently in

26

reperfusion injury. Mitochondrial fission is strongly linked to mitochondrial deterioration during
insulin resistance in skeletal muscle but has not been shown in cardiac muscle87. Finally, chronic
alterations in mitochondrial fission can affect a population of small, isolated mitochondria that
are a target for the process of selective autophagy.
3.1.3.Autophagy of mitochondria It was recently revealed, in 2008, that selective fission and
fusion of mitochondria creates two segregated populations. One group presents with disrupted
membrane potentials and are subsequently broken down through the process of autophagy88.
After further research in yeast and mammals, the process of mitochondrial specific autophagy or
mitophagy was characterized. Beclin1 is a protein found on the initiated phagophore and during
elongation, LC3 becomes incorporated into the phagophore. LC3 is a key protein on the
developing phagophore that can bind specific OMM proteins and lead to complete destruction of
the separated portion of the organelle through marcoautophagy. LC3 interacting molecules that
have been identified including BNIP3/NIX, FUNDC, cardiolipin (when present on OMM), and
Parkin recruited p6289,90. By selectively destroying damaged or mutated mitochondria, a cell can
protect itself from accumulation of ROS and somatic mtDNA mutations that can be deleterious
to the cell91. As yet, no study has specifically determined the functions of mitochondrial specific
autophagy in cardiomyocytes though it has been seen that in Atg5 KO mice (loss-of-function for
general autophagy), cardiac disease is present with oxidative maladies 92. During cardiac stress
(ischemia/reperfusion), autophagy seems to play an important role and may contribute to cardiac
protection93,94. These studies, while opening the door for further research, indicate that
mitophagy plays an invaluable part in the protection against heart disease by removing damaged
and ineffective mitochondria from the cell.
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3.1.4.Biogenesis of mitochondria As we’ve seen, mitochondria make up a large proportion of
the mass of cardiac cells to allow constant energy production. During embryonic development,
glucose is a preferred fuel source but during stem cell maturation, mitochondria become more
abundant thus the cell can rely more on fatty acids for energy through adulthood 95. This process
of generating new mitochondria during early development is termed mitochondrial biogenesis. In
the myocardium, a surge of mitochondrial biogenesis at birth allows the development of a
remarkably dense array of mitochondria packed tightly between sarcomeres 96–98. After this
developmental stage and into adulthood, mitochondrial biogenesis is far less important compared
to maintenance of fatty acid oxidation capabilities of existing mitochondria 99. As mentioned,
occasionally, mutations or disruptions in membrane potential warrant fission of small portions of
a mitochondrion and selective destruction by autophagy. As this occurs, cardiac cells would
progressively lose oxidative capacity over the lifespan if this same process of mitochondrial
biogenesis did not replace functional organelles. Three groups of transcription factors appear
responsible for the replication of mitochondria from existing mitochondria (rather than de novo):
PPARs, ERRs, and NRFs. PPARs appear to aid in the regulation of genes involved in
mitochondrial (and peroxisomal) fatty acid oxidation100. ERRs are a family of nuclear receptors
that are involved in most mitochondrial metabolic pathways including TCA cycle components,
β-oxidation, and oxidative phosphorylation101. NRFs are primarily involved in the regulation of
genes controlling the OXPHOS components102. PGC-1α is a transcriptional coactivator that can
coordinately activate each of these transcription factors and stimulate mitochondrial biogenesis
in the cardiac muscle cell103,104. During pathological cardiac remodeling, mitophagy seems to
play a key role in controlling ischemic damage but less is known about how mitochondrial
biogenesis restores the damage organelles93. Speculation puts mitochondrial biogenesis in an
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important position during exercise stressors, pregnancy responses, preconditioning and
carioprotective processes in the heart muscle cell97.
3.2.Mitochondrial Genetics Mitochondria are a defining characteristic of eukaryotic cells and
result from an ancient α-proteobacterial endosymbiotic interaction105. This helps explain the
presence of a circular genome within the mitochondria (mtDNA) that is highly variable between
species106. The mtDNA has shortened dramatically and independently throughout genetic
lineages with most of the still necessary genes having been transferred from the mtDNA to the
nDNA. Evidence supports the evolutionary advantage of transferring genes from mtDNA to
nDNA to mitigate mutations by allowing sexual recombination and lessened proximity to
oxidative stressors107. Still, not all genes encoded by mtDNA can be successfully expressed from
the nucleus108. This presents key questions as to the importance of the genes expressed by the
mtDNA, and how to control of replication, transcription and translation of the mtDNA.
3.2.1.The mitochondrial genome Mitochondrial DNA has shown extensive alterations
phylogenetically in the eukaryotic domain but remain relatively unchanged within kingdom
Metazoa106,109. A high degree of homology exists between mammals, especially mouse and
man110,111. Human mtDNA is ~16.6kb, double stranded (a heavy and a light strand based on base
composition), and encodes 37 genes comprised of two rRNAs, 22 tRNAs and 11 mRNAs. Two
of the mRNAs are bicistronic and therefore, each becomes 2 proteins making the total number of
mtDNA-encoded proteins thirteen112. Maintenance and expression of the mtDNA is vitally
important in mammals. Maintaining the discreet genome and associated machinery for
expression seems to evolutionarily outweigh the benefit of transferring the sequences for 13
mtDNA encoded proteins to the nDNA because over one quarter of the mitochondrial proteome
is involved in DNA maintenance, replication and expression113,114.
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3.2.2.mtDNA Replication mtDNA replication is distinct from that of nDNA replication and as
such has specialized replication machinery. mtDNA replication machinery has been related to
the replication machinery of early bacteriophages115. A specialized DNA polymerase-γ maintain
DNA binding, exonuclease, and lyase activity, TWINKLE aids in helicase unwinding of the
mtDNA, and RNA polymerase contributes the primers for the polymerase process116–120. The
light strand promoter region is ~200bp 5’ of the heavy strand origin of replication allowing for a
3’ tail from RNA polymerase to act as the primer initiating heavy strand DNA replication. The
primer is later cleaved by nucleases while replication continues121. MtDNA copy number is
under control of multiple replication abortive processes but can be stimulated by overexpression
of TWINKLE in mouse muscle and heart 122. mtDNA is compacted into nucleoid structures
similar to that of bacterial genomes to allow a more densely packed organization. The primary
molecule forming the nucleoid structures is TFAM capable of binding the mtDNA every 1617bps123. The control of mtDNA compaction by TFAM is relevant to both levels of mtDNA
replication and transcription124.
3.2.3.mtDNA repair mechanisms mtDNA is in relatively close proximity to redox centers and
mutation causing free radicals (as discussed in section 5). However, little evidence suggest that a
faithful or dedicated repair process for mtDNA is present. However, some evidence does suggest
a limited ability for mtDNA mutations to be corrected. Research has shown that base excision
repair is partially active within the mitochondria and helps mitigate oxidative DNA damage.
Mismatch repair mechanisms are lost from nDNA to the mtDNA but Polγ (the only polymerase
located within the mitochondria) has a specific subunit for proofreading thus minimizing the
need for mismatch repair. Base dimerization and crosslinking mutations cannot be repaired
effectively. Some ligase activity does occur because blunt ends and linear fragments can be
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rejoined. Certain proteins have been identified that function in these processes with nDNA and
are localized to mtDNA. As yet, it does not appear that a robust mtDNA repair system is active
within the mitochondria. Because no recombination, if a somatic mutation occurs it will: 1) be
silent, 2) prevent transcription or replication and be destroyed, 3) create mutated genes/proteins
and propagate to daughter mitochondria. These mutation, especially in a mothers’ egg, can create
diseases with a wide array of clinical symptoms. Other theories suggest that a slow rate of
mutation over lifespan can reduce oxidative potential of the mitochondria and cause aging and
death125–131.
3.2.4.mtDNA Transcription MtDNA contains two anti-parrellel strands with the outer strand
being slightly heavier due to a higher proportion of guanine base pairs and thus is referred to as
the heavy strand (while the complimentary is the light strand) 132. The mtDNA is tightly packed
with only one non-coding region used to regulate transcription of each strand with the LSP and
HSP. Beginning transcription in this non-coding region produces mRNA transcripts that are near
the length of the entire genome with termination sequences stopping transcription before
completing circumscription. These polycistronic transcripts produce multiple mature mRNAs
that are processed co-transcriptionally and seem to use intermittent tRNAs to ‘punctuate’ or
flank the rRNAs and mRNA coding sequences133. The molecular machinery used for mtDNA
transcription is similar to that of replication and involved a mtDNA-directed RNA polymerase
(mtPol ), a subunit of DNA polymerase-γ, and TWINKLE helicase activity134. mtPol was
identified based on sequence homology to yeast and the x-ray structure identifies an N-terminal
promoter-binding region and a C-terminal catalytic domain135–137. mtPol is able to bind the
promoter region but is not able to begin transcription without additional transcription factors.
Mitochondrial transcription factor B2 (TFB2M) is required to aid in the initiation of transcription
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but is dissociated from the Polymerase complex after leaving the promoter region and beginning
elongation138–140. Transcription factor A (TFAM) additionally aids in the transcription initiation
complex by its role in DNA binding and compaction into a U-turn shape without sequence
specificity. These shapes aid in denaturing a small portion of the mtDNA which can create an
area for transcription initiation on the promoter region141–143. Transcription initiation models
suggest that TFAM first binds ~70-75bp upstream of the start sequence creating a bend in the
DNA and associating with mtPol to recruit it to the promoter site. As it binds ~50bp upstream of
the TSS, mtPol recruits TFB2M to surround the TSS and help generate the first phosphodiester
bonds, the rate limiting step in transcription144. Transcription elongation is aided by
mitochondrial transcription elongation factor that aids in polymerase activity especially where
secondary RNA structures or oxidative damage on DNA basepairs (8-Oxo-2’deoxyguanosine)145,146. Mitochondrial transcription termination was thought to be controlled by a
family of termination factors (MTERF 1-4) however only MTERF1 seems to play a role in
transcription termination. The H-strand seems to have a short and long transcript size that
transcribes the entire H-strand or just the first 4 genes with MTERF1 controlling the early
termination for yet unknown reasons147–149. The role of MTERF2,3 and 4 have been identified
but even with sequence similarity and sequence specific DNA binding motifs, evidence suggests
they have now taken on roles in replication initiation and ribosomal assembly150–152.
3.2.5.mt-mRNA Translation Of the >250 proteins localized to the mitochondria to aid in DNA
processing, transcription and replication, they are all required because of the necessary outcome
of mitochondrial translation and the few (13 in mammals) necessary proteins153,154. This requires
maintenance of the requisite translation machinery including mRNAs, tRNAs, and ribosomes but
huge disparities exist between cytosolic, bacterial, and mitochondrial translation. Almost all of
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the requisite proteins for mitochondrial translation, across all species, are encoded by nDNA and
must be imported into the mitochondria155.
3.2.5.1.tRNAs While mitochondria originated form a common ancestor, many of the
components of translation are substantially different between animals and bacteria. A primary
example is the difference in the mammalian mitochondrial genetic code from that of the
universal genetic code156. The mitochondrial code in mammals contain more stop codons and an
extra Trp codon compared to the universal norm and contain fewer tRNAs than would be
predicted with the traditional wobble rule. Among Metazoans, the majority of mt-tRNAs contain
a traditional cloverleaf shape whereas some other eukaryotes contain simplified codon/anticodon fragments only157,158. This is most apparent when the structures for the mitochondrial
ribosomes was revealed and showed striking differences among species.
3.2.5.2.rRNAs and mitochondrial ribosomes The structure of mitochondrial ribosomes, or
mitoribosomes, has changed dramatically across evolution but maintains similarity among higher
organisms159–161. The mammalian mitoribosome can sediment as a 55S monosome consisting of
a 28S SSU and a 39S LSU which contain a 12S and 16S mt-rRNA, respectively162. Bacteria
maintain a 5S rRNA which is involved in coordination of the LSU and SSU during translation 163.
Modern mitochondria do not contain this small rRNA and instead, have evolved the interacting
regions of the ribosomal subunits to compensate164. Despite the differences seen among
mitoribosomal architecture, the catalytic active site remains constant between bacteria and
mitochondria explaining side effects of many antibiotic treatments 165. An additional
responsibility of the mitoribosome is insertion of the nascent protein into the IMM. Each of the
proteins encoded by mt-DNA are IMM proteins in the OXPHOS and are highly hydrophobic
which may contribute to reasons why they cannot be encoded by nDNA108. The exit tunnel of
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mammalian mitoribosomes has developed a similarly hydrophobic protein lining to mimic the
protein folding necessary for membrane insertion159. Additionally, a ribosomal interatcting
protein is anchored within the IMM and binds near the exit tunnel of the mitoribosome. Lastly,
specific proteins such as Oxa1 interact with the nascent chain and acts as a protein insertase for
the IMM though it Is not absolutely required166,167.
3.2.5.3.Translation initiation Protein synthesis is an energetically expensive process and as
such, translation initiation is generally a committal step. To begin translation requires specific
interactions of all proteins and RNA molecules involved. In bacterial and eukaryotic translation,
the process has been reconstructed in vitro using just this minimal necessary components but this
has not been fully achieved using mitochondrial translation machinery alone168. Still, these
experiments have shed much light on how the translation initiation process takes place. The
working theory is that a preinitiation complex made up of the combined 55S mitoribosome is
bound by mtIF3 which dissociates the 28S SSU and 39S LSU revealing a binding site for mtIF2
on the 28S SSU. mtIF2 is able to recruit the fMet-tRNA bound to the start codon on the mRNA
to the P site within the 28S SSU. mtIF2 then hydrolyzes GTP to GDP allowing the 39S LSU to
join by removing the two initiation factors. This generates the initiation complex consisting of
the 55S mitoribosome, and mRNA bound by the appropriate aminoacylated tRNA153.
3.2.5.3.1.mtIF2 Comparisons are generally made between mammalian mtIF2 and IF2 of bacteria
because it is no more dissimilar than that of yeast mtIF2. Mammalian mitochondria only contain
one Met-tRNA used for both initiation and elongation. A Met-tRNA transformylase has been
identified that generates a subset of fMet-tRNAs to be used for initiation while the nonformylated Met-tRNA bind to mtEF-Tu for elongation169. mtIF2 will bind fMet-tRNA at a
subdomain labeled VIC2. Domain III of mtIF2 is responsible for the binding to the 28S SSU
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though this association constant is highly dependent on the presence of GDP. Because of this
reliance on GDP, Domain IV removal eliminates 28S binding capability as the GDP binding
domain170. Bacterial and eukaryotic cytoplasmic translation initiation utilize 3 ‘universal’
translation initiation factors (1,2, and 3) however this is not the case for the mitochondria. No
equivalent of IF1 has been identified in mitochondria. There is a 37 amino acid insertion after
Domain V of the mtIF2 protein that shows similar activity of the IF1 protein in prokaryotic
systems. In an E. Coli system, mutants lacking IF1 and IF2 were lethal but could be rescued by
replacing mtIF2 showing that within the mitochondria, a single initiation factor does the work of
two bacterial initiation factors171,172. The function of bacterial IF1 that was taken on by mtIF2 is
that of binding the 30S SSU covering the A-site until the fMet-tRNA is bound and the
preinitiation complex is formed173.
3.2.5.3.2.mtIF3 mtIF3 shows only a small degree of homology with bacterial IF3 and no
homolog has been identified in Saccharomyces cerevisiae174. The protein has not been isolated
from mitochondria but sequence prediction indicates C-terminal α-helical regions similar to that
seen in E. Coli and other bacteria as well as a flexible inter-domain linker region. The N-terminal
portion is predicted to be unstructured in solution but develop a structure once associated to the
ribosome175–177. This flexible linker is thought to play a role in its ability to bind the 55S
mitoribosome and dissociate the large and small portions to all mRNA and fMet-tRNA binding
to the P-site. mtIF3 is also able to stop translation from proceeding when an improper start codon
is placed in to the ribosome, or when fMet-tRNA associates with the P-site without a bound
mRNA178. This activity acts as a proofreading step preventing mt-mRNA translation initiation
under inappropriate mRNA/tRNA combinations. Which mitoribosomal proteins are targeted and
bound by mtIF3 and their location in the mitoribosomal subunits is not yet known179.
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3.2.5.4.Translation elongation Mitochondrial translation elongation is highly conserved from
prokaryotes to mammals180. Elongation proceeds when a ternary complex consisting of mtEFTu, an aminoacylated-tRNA, and GTP associates with the A site and forms a complimentary
codon:anticodon interaction. GTP is hydrolyzed to GDP by mtEF-Tu to generate a new peptide
bond elongating the nascent chain. mtEFG-1 subsequently binds to the mitoribosomal complex
at the A site, hydrolyzes GTP, and translocates the nascent peptide to the P site opening the A
site for the next mRNA/mtEF-Tu/GTP ternary complex. Simultaneous to mtEF-G1 GTPase
activity, mtEF-Tu interacts with mtEF-Ts to aid in the removal of GDP and replace the GTP on
mtEF-Tu to allow subsequent recycling181–188.
3.2.5.4.1.mtEF-Tu mtEF-Tu was originally identified because of high expression in tumor cells
in 1995 and was characterized in Bos taurus189. The gene has only a short mitochondrial
targeting sequence and results in a 45kDa protein that has high homolog with the bacterial
counterpart. This is consistent with the mostly conserved process of translation elongation from
bacteria to mitochondria190. The crystal structure of mtEF-Tu reveals 3 domains and a strong
interaction with mtEF-Ts. Domain I binds GTP/GDP, domain II binds aa-tRNA and the
mitoribosomal SSU, and domain III further interacts with the 5’ stem of the aa-tRNA191–193.
These features allow bovine mtEF-Tu to function well in E. Coli but the conformational changes
associated with tRNA codon:anticodon binding and Domain I are not strong enough to catalyze
GTP hydrolysis194.
3.2.5.4.2.mtEF-Ts The primary function of mtEF-Ts is to aid in guanine nucleotide exchange
with mtEF-Tu. The crystal structure reveals extensive binding between mtEF-TS and mtEF-Tu at
three particular domain interactions191. Further experiments nucleotide exchange in mtEF-Tu
through the aid of mtEF-Ts requires multiple important steps including removal of bound Mg 2+,
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stabilization of GTP at the β-phosphate, and conformational changes that affect the hydrogen
bonding with the mitoribosome and aa-tRNA195–198.
3.2.5.4.3.mtEF-G1 mtEF-G1 is the main protein controlling the translocation step of
mitochondrial translation elongation and involves GTP hydrolysis activity199,200. The GTPase
activity requires specific activity from portions of the mitoribosomal LSU200 but very few other
enzymatic experiments have been performed limiting out knowledge on the functional
characteristics of mtEF-G1201.
3.2.5.5.Translation termination In mitochondria, UAA and UAG serve as stop codons while
UGA is replaced. When the stop codon enters the A site of the 55S ribosomal complex, it is
recognized by the GTP bound mtRF1a activating the GTP hydrolysis to allow the release of the
now completed polypeptide chain. Subsequently, mtRRF1 and mtRRF2 (mitoribosome recycling
factors) dissociate the two mitoribosomal subunits to allow for ribosomal recycling 202.
3.2.5.6.Translation Activators Translational activators were first reported in 1989 and 1990
from yeast models where research identified a nDNA-encoded protein that localized to the
mitochondria and activated translation203–206. Translational activators are able to enhance mtmRNA translation by binding (with sequence specificity) to mt-mRNAs, the mitoribosome, and
tethering to the IMM where the nascent peptide is to be inserted 207. These translational activators
have implication on feedback loops and in controlling the number of key subunits for OXPHOS
components. The only known human translational activator is responsible for COX1 translation
and assembly208,209. An additional mechanism implicated for activation of mitochondrial
translation is through microRNAs interacting with AGO2 210. These results are controversial and
have yet to be confirmed because other transcriptomic approaches have not identified microRNA
enrichment in isolated human mitochondria211.
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3.3.Mitochondrial DNA-encoded proteins The 13 proteins that are generated as a result of the
mtDNA expression system are necessary to generate the OXPHOS system212. These mt-DNA
encoded proteins are assembled with proteins from the nDNA into the IMM and allow the
OXPHOS system to function. These proteins are incorporated into subunits I, III, IV, and V 213.
Further detail on the function of these proteins within the OXPHOS complexes and the ETS as a
whole follows.
4.Electron Transport and Oxidative Phosphorylation The chemiosmotic theory of ATP
synthesis in cholorplasts and mitochondria was originally proposed by Peter Mitchell in 1961214.
This model explained that a proton gradient formed across a membrane space and that the
electrochemical potential energy that formed across this membrane could be used to drive
phosphorylation of ADP to generate ATP. This provided for a mitochondrial model accounting
for a series of electron transfer reactions which electrons from O2 to produce H2O with the
subsequent energy yield moving protons across the IMM against the concentration gradient. This
provided an ATP-less mechanism to generate the gradient for the ATP synthase pump to make
ATP215,216. This findings were confirmed by the development of a method to reconstitute the
proteins into a biological membrane and measure the rates of proton pumping using pH
indicators217. The OXPHOS system consists of: 3 proton pumping complexes (I, III, and IV),
succinate dehydrogenase, two electron carriers (coenzyme Q/ ubiquinone and Cytochrome C),
and finally the ATP synthase energy generating pump.
4.1.NADH:ubiquinone oxidoreductase Complex I of the ETC completes the overall reaction of
transferring electrons from NADH to ubiquinone by a series of redox reactions to pump protons
across the IMM. Complex I is made up of 45 distinct protein subunits though 14 of these are
highly conserved and sufficient for energy transduction. Of the 14 core proteins, seven are
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hydrophilic and extend into the matrix of the mitochondria and are encoded by nDNA while the
other seven create a hydrophobic intermembrane arm extends through the IMM. Each of the
seven core subunits within the membrane arm is encoded by mtDNA and translationally inserted
into the membrane. The seven mtDNA-encoded proteins are: ND1, ND2, ND3, ND4, ND5,
ND6, and ND4L. These molecules contain between three and 16 transmembrane helices and thus
are extremely hydrophobic, possibly contributing to their conservation in mtDNA. It is predicted
that these ND subunits create antiporter-like half channels through the membrane and allow
transfer of protons halfway connecting with a subsequent half channel to complete the
translocation. These channels are thought to be filled with water molecules and act with a
Grotthus–like mechanism whereby the protons are not translocated but rather exchanged
between water molecules to allow more rapid movement. This would allow uncoupled leakage of
protons across the membrane if no gating took place. The energy to use these channels against a
gradient is generated distally from the ND channel subunits. In the hydrophilic arm within the
matrix, NADH is oxidized to NAD+ transferring the electron to Flavin mononucleotide
generating FMNH2. The oxidized NAD+ is returned to the mitochondrial matrix to replenish the
pool of substrates for the TCA cycle or β-oxidation. The reduced FMNH2 transfers its electron to
a series of seven FeS clusters that rapidly transfer the electron from the periphery of the complex
towards to membrane-bound portion. At the FeS cluster nearest the membrane, ubiquinone
accepts the electron and becomes the reduced ubiquinol. An α-helical subunit of the complex
runs lengthwise from the electron transport centers to the membrane bound arm and is theorized
to aid in the coordination of electron transfer to proton pumping. The FMNH2 intermediate can
react with molecular O2 to produce O2- (superoxide) because of the low reduction potentials of
the FeS clusters within complex I. Ubiquinone is reduced to ubiquinol (a 2-electron reaction) by
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2 one-electron steps involving a semi-quinone intermediate. The predicted stoichiometry moves
2 electrons from NADH to ubiquinone (generating NAD+ and ubiquinol) and allows the
movement of ~4 protons from the matrix to the intermembrane space 218.
4.2.Succinate dehydrogenase Succinate dehydrogenase is considered an enzyme within the
TCA cycle as well as complex II of the ETC complexes. The complex is made of four subunits
tethered to the IMM. The subunit SDHA catalyzes the succinate to fumerate redox reaction
generating the electrion donor FADH2 as part of the TCA cycle. SDHB is able to accept FADH2
from the SDHA reaction or from other sources such as β-oxidation. SDHB transfers two
electrons from FADH2 through three FeS clusters to a heme prostetic group within the SDHC/D
membrane-bound portion of the complex. The heme prostetic group interacts with ubiquinone
allowing two subsequent single electron reactions to generate ubiquinol similar to complex I.
Complex II is far smaller than the other ETC complexes and contains zero proteins encoded by
the mtDNA. Additionally, it only accepts electrons from FADH2 and does not pump any protons
during the electron transfer meaning it does not contribute to the electrochemical gradient across
the IMM. This explains why FADH2 contributes less to ATP production than NADH219. The
reduced ubiquinol molecules from complex I and II are able to transfer electrons further down
the ETC to complex III.
4.3.Cytochrome bc1 oxidase Complex III of the ETC is also appropriately named cytochrome
bc1 (due to the reaction intermediate) or ubiquinol:cytochchrome C oxidoreductase (based on the
overall redox reaction). In mammals, this complex is composed of eleven protein subunits of
which three subunits are necessary for electron transport function: Cyt b, Cyt c1, and ISP. Cyt B
is the only protein of this complex that is encoded by mtDNA while the rest are encoded in
nDNA. Cyt B is completely embedded within the IMM and contains two of the key redox
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intermediates as b-type heme prosthetics, heme bL and heme bH. The other two core proteins are
Cytochrome c1 (containing a c-type heme prosthetics) and an iron sulfur protein (ISP, containing
the FeS clusters). The complex functions by undergoing two rounds of the Q-cycle reactions.
The first series transfers two elections from a ubiquinol molecule (product of Complex I and II) –
one to a FeS cluster and another to heme bL to transfer two protons. The electron from the FeS
cluster is passed to the heme c prostetic on cyt c1 and then to a membrane diffusible carrier
cytochrome C. The electron on the heme bL is transferred to heme bH and then to an oxidized
ubiquinol to create a semiquinone intermediate. A second round of this cycle will take place to
further reduce the semiquinone to ubiquinol and pumping two more protons across the IMM. In
total, 4 protons are pumped to the intermembrane space, 2 cytochrome c molecules are reduced,
and 1 ubiquinol is oxidized to ubiquinone. The Q-cycle will continually to transfer electrons
to/from ubiquinol/ubiqinone/semiquinone. This ceaseless transfer of electrons will cause some
leakage of electrons to O2 generating O2-. This occurs to a low extent during normal electron
transport, to a greater extent during excess ETC reduction, or if the transfer of electrons to the
FeS clusters is blocked by an inhibitor such as Antimycin A. Both the semiquinone intermediate
and the initial transfer of electron into the complex occurs with the heme bL acceptor in the Cyt b
protein – the sole protein encoded within mtDNA220. The reduced cytochrome c molecule
diffuses in the IMM to complex IV for further electron transport.
4.4.Cytochrome c oxidase Complex IV of the ETC oxidizes cytochrome c from the reactions of
complex III and transfers the electrons to O2 to form H2O. The complex is composed of 13
subunits of which the three core subunits are encoded by mtDNA and are responsible for
electron transport. The three subunits encoded by the mtDNA are the largest and most conserved
showing homology to bacterial proteins. Similar to complex I and III, the mtDNA encoded
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subunits make up the functional components of the complex. In complex IV, COXI (subunit I)
contains hemea, hemea3, the copper center Cub, and the molecular O2 that is to be reduced to
H2O. COXII (subunit II) contains the Cua center. The function of the final mtDNA-encoded
subunit, COXIII is less understood. In a redox cycle of complex IV, cytochrome c (from reduced
from complex III) transfers two electrons to Cu a on COXII, then to hemea, hemea3, and Cub on
COXI then finally to oxygen forming H2O and resulting in 4 protons being pumped to the
intermembrane space. The full series of reactions uses 4 reduced Cytochrome C donors, one
molecule of O2, and 8 protons to generate 2H2O molecules and pumping the remaining 4 protons
across the membrane. While Complexes I and III are generally accepted as the primary,
physiological sources of ROS production (and potentially Complex II through new evidence),
Complex IV has long been controversial as it relates to production of O2 -. Generally, Complex
IV does not produce any physiologically relevant amount of ROS but can be a contributor under
hypoxic stress as the redox centers become completely reduced221–223. This is the final complex
associated with electron transport to create the proton motive force across the IMM. To couple
the electron transport to oxidative phosphorylation requires proper functioning of the F 0/F1 ATP
synthase, or Complex V.
4.5.F0F1 ATP Synthase ATP synthase, or sometimes ATPase is the fifth and final complex of
the OXPHOS system. ATP synthase is an enormous protein complex with a complicated
structure involved a membrane bound portion, a matrix, soluble portion, and a ‘stator’
connecting the two. The central, rotating F1 portion bind ADP and Pi and rotates to combine the
two into ATP before releasing the newly generated energetic molecule. This F1 portion is linked
to the F0 membrane bound portion which rotates in response to protons flowing through a
membrane channel, with the concentration gradient. This flow of protons along the concentration
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gradient acts to rotate the c subunit ~20-30o per proton. This rotation is transferred to the F1
portion through a γ[epsilon] neck resulting in ~120 0 of rotation in the F1. This is sufficient to
allow a conformational change of the ADP + Pi binding subunits into a tight confirmation
generating ATP. After another series of protons is moved, and the F1 portion continues to rotate,
the ATP will be released allowing subsequent ADP phosphorylation. Of the numerous proteins
involved in this complex molecular engine, two subunits are encoded by mtDNA in mammals.
The genes ATP6 and ATP8 encode the ATP synthase proteins mt-ATP-a and mt-ATP-A6L.
Similar to the other mtDNA-encoded proteins, these are extremely hydrophobic and integrated
deep within the membrane. They also seem to play key roles in the function of the protein
complex. Subunit a is a primary transmembrane component of the proton channel that allows the
H+ to travel across the IMM. Subunit A6L contributes to this as well by connecting subunit A to
the F0 subunit c which is rotating in response to proton movement 224–231. These are the last two
protein examples encoded by the mtDNA and finalize the continuing theme of the primary
importance of the mitochondrial genetic machinery to maintain aerobic life.
5.Reactive Oxygen Species As described above, electrons move quickly and coordinately along
the ETC to facilitate the development of the proton gradient (Δψm) from ATP synthesis. At
certain key transfer steps, electrons can react with unintended acceptor molecules. Molecular O 2
is able to act as a single electron acceptor generating O2-(superoxide). Superoxide then rapidly a
dismutase and H2O to generate H2O2 (hydrogen peroxide). The instability of the peroxide bond
results in H2O2 having high reactivity and readily transferring an electron to any acceptor
molecule so that it can be oxidized back into H2O. Superoxide, hydrogen peroxide, among other
unstable electron donors are termed reactive oxygen species (ROS) because of their propensity to
oxidize and transfer a free electron radical to a reducing molecule. This section will discuss
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sources of O2- within the mitochondria, deleterious effects of excessive ROS and mechanisms to
mitigate free radicals using anti-oxidant defenses.
It should be noted that this section details the production of superoxide and its products
from mitochondria as a source. Other forms of free radicals exist from sources such as
cytoplasmic xanthine oxidases, catechols, transition metals (Cu 2+, Fe2-), membrane
lipooxygenases, prostaglandin synthesis, lysosomal peroxidases, peroxisome oxidases, and
NADPH oxidases.
5.1.Production of superoxide Diatomic oxygen is the final electron acceptor of the ETC to be
transformed into water but when O2 accepts a single electron, it becomes superoxide by
univalent reduction. This is the main ROS species of interest and is the direct result of imperfect
redox exchanges along the IMM. Other species of ROS are generally formed through subsequent
interactions with O2-. The primary sources of O2- have been identified as Complex I and III of the
ETC and this can occur through multiple reactions. Categorically, the source of the electron
donor within Complex I or III suggests the redox state and Δψm that could be expected to result
in excess O2- production: either a NADH/NAD+ isopotential source or Q/QH2
(ubiquinone/ubiquinol) isopotential source232–234.
5.1.1.NADH/NAD+ isopotential A group of redox enzymes is capable of producing O2- based
solely on the redox state of NADH/NAD+. These reactions involve a flavin molecular
intermediate to assist in the redox reactions which is the source of the electron singlet. This mode
of ROS production might be seen in mitochondria undergoing very low ATP production but with
high amounts of energy substrate such as NADH. [NADH] is generally downregulated under
physiological conditions to prevent this from occurring naturally. It can be seen experimentally
by inhibiting electron flow to ubiquinone as with rotenone. These [NADH]/[NAD+] sensitive
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reactions are: 1) Complex I Flavoprotein reduction, 2) pyruvate dehydrogenase, 3) branched
chain keto acid dehydrogenase and 4) α-ketogluterate dehydrogenase. Predictive experiments
show that complex I FMN does not relatively contribute much to the total superoxide pool
compared to the other enzymes in this group. In fact, α-ketogluterate dehydrogenase is predicted
to produce 8 times as much O2 - as FMN from complex I.
5.1.1.1.Mechanisms of O2- generation The complex I acceptor of NADH electrons is a Flavin
mononucleotide (FMN) and if FMN becomes fully reduced (such as occurs when the ubiquinol
is fully reduced through increased [succinate] or rotenone), the FMN will transfer electrons to
O2- because the FMNH2 is exposed to the aqueous phase. Pyruvate dehydrogenase (PDH) is
under allosteric control of NADH such that under highly reduced conditions, [NADH] is
increased and activity of PDH is decreased. This allosteric regulation prevents the flavin
prosthetic group from donating an electron to NAD+. When PDH is fully reduced, this will result
in the electron singlet reducing O2 to form superoxide. Branched chain keto acid dehydrogenase
catalyzes branched chain amino acids for entry into the TCA cycle. This enzyme shows a similar
mechanism of superoxide generation as PDH. It is not under direct control of [NADH] but
upstream molecular activators are involved in metabolic sensing. α-ketogluterate dehydrogenase
uses a similar flavoprotein as PDH but is under tight allosteric control of NADH.
5.1.2.Q/QH2 isopotential As mentioned in Section 4, Complex I and II transfer electrons to a
carrier molecule ubiquinone and ubiquinol subsequently reacts at the Q-cycle within Complex
III. This major electron transfer point does contain a other, less significant electron donors to the
ubiquinol pool: Electron transfer flavoprotein:ubiquinone oxidoreductase (ETFQO),
dihydroorotate dehydrogenase (DHODH), proline dehydrogenase (ProDH), G3PDH,
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Succinate:quinone reductase (SQR) in addition to the canonical reactions of SDH (complex II)
and complex III.
5.1.2.1.Mechanism of O2- generation For each of these redox controllers, an electron is
transferred to the oxidized ubiquinone to generate a semiquinone intermediate or reduced
ubiquinol. Under circumstances of excessively high Δψ m, concentration of reduced ubiquinol can
increase and cause the Q/QH2 ratio to shift towards reduction. This prevents ubiquinol from
accepting electrons from any of the donors in this isopotential group. This, in turn, forces
reduced ubiquinol within the complex I CoQ domain to transfer electrons to O2 generating O2and generating a ubiquinone that can accept the donor’s electron. The concept of the ETC
reducing backwards towards complex I is referred to as reverse electron transport. This
mechanism accounts for the contribution of each of these enzymes to superoxide production.
5.2.ROS chemistry and deleterious effects Superoxide is a direct product from the
mitochondrial electron transport processes but is only one of the ROS. Superoxide, however, has
low reactivity with most organic molecules but will readily interact with other molecules (Fe 2+,
FeS clusters, NO-, and another O2-) including as a substrate for dismutase enzymes generating
H2O2. H2O2 is able to diffuse across biological membranes or use aquaporins to mobilize
throughout the cell235. H2O2 can also interact with metal ions (Cu+, Fe2+) to generate a hydroxyl
radical (-OH). -OH is the most reactive form of ROS and interacts with most organic molecules
rapidly236. The reactive free radicals are capable of targeting cellular macromolecules and
interacting to cause damage using hydrogen abstraction reactions.
Lipid peroxidation is an example of such a reaction that targets unsaturated fatty acids
generating a peroxyl-fatty acid radical. This radical can oxidize using another fatty acid to
become a fatty acid peroxide and another fatty acid radical which can propogate the reaction.
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This can lead to a series of fatty acid modifications in a region such as a membrane thus causing
negative consequences to ion channels, membrane enzymes, transport proteins and altering the
composition of the lipid bilayer236.
Protein damage results from the interactions of free radicals with specific amino acid
residues. Specifically, sulfhydryl groups are at risk in cysteine and methionine residues of
becoming sulfoxides. Ring cleavage is possible in histidine and tryptophan residues. Other
residues may form aldehyde or ketone carbonyls. All of these changes can alter structure and/or
function of the peptide molecule. This will generally result in alter function of the protein and
eventual proteolysis through the proteasome or lysosomal degradation. ROS can also directly
interact with protein post-translational modifications to stabilize or destabilize specific signaling
pathways as seen with ROS-induced stabilization of HIF-1α in the response to hypoxia. The
proteolytic processes may be overwhelmed generating an abundance of dysfunctional protein
aggregates237–244.
Carbohydrates and sugars can interact with free radicals and amino acids to produce
advanced glycation end products. These are amino acids that have been irreversibly altered by a
carbohydrate to the extent that they cannot enter the 20S proteasome for degradation245.
RNAs, which are already unstable in nature, can be oxidized by free radicals and
truncated altering protein synthesis and resulting in abnormal protein translation,247.
DNA can be oxidized by ROS at both the base and the deoxyribose sugar 248,249. The cell
generally maintains a robust DNA damage/repair response but this too can become overwhelmed
in situations of chronic, excessive ROS production250,251. nDNA oxidation has specific interest
to those interested in radiation induced cancer generation but is of interest here because of the
quantity of mitochondrial ROS produced in the ETC and the proximity to mtDNA for mutations.
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ROS are able to react with DNA rapidly. Deoxyribose is bound to two phosphate at the 3’ and 5’
carbon. Each of these interact with an oxygen molecule on the PO 3γ. The interacting oxygen
(from either the 5’ or the 3’ phosphate) can be oxidized by the free radical thus causing a single
strand break252,253. Additionally, the DNA bases can be altered biochemically by ROS. Thymine
can be reduced to form an enol base thymine-glycol that interferes with DNApolymerase.
Guanine and adenine can be hydroxylated creating lesions in DNA. Other DNA oxidation
products include 2-hydroxyadenine, 5,8-dihydroxycytosine, and 5-hydroxymethyluracil. At least
24 known alterations to DNA bases have been identified as products of ROS interactions. Each
of these can cause mutations when replicated or inhibit transcription/replication unless repair
mechanisms can compensate. Some mutations such as the 8-hydroxyguanine has no known
repair mechanism because it is recognized as a different base254–258.
5.3.Mitigation of ROS Free radicals are constantly generated by the cell and especially within
the mitochondria but the damage that is associated with free radicals is generally mitigated by
the cell in a series of mechanisms responsible for ROS homeostasis. Before ROS is even
produced, uncoupling proteins embedded within the IMM are able to help control Δψm in such a
way as to prevent ETC reduction and ROS formation259. However, once O2- is formed, the
antioxidant system must come into play. The primary proteins involved in the antioxidant
response are: 1) superoxide dismutase enzymes (SODs) which convert superoxide into hydrogen
peroxide, 2) catalase which converts hydrogen peroxides into water, and 3) glutathione
peroxidases which neutralize hydrogen peroxide by using reducing equivalents from reduced
glutathione. Cytochrome C is a basic electron acceptor within the IMM and transfers electrons
from complex III to complex IV of the ETS. Antioxidant activity has been demonstrated in
Cytochrome C of isolated mitochondria and this can further contribute to proton pumping for

48

proton gradient and ATP production260–264. An isoform of SOD, SOD2 is specifically localized to
the mitochondrial matrix for ROS detoxification265–269. While the family of SOD proteins does
mitigate superoxide effectively, H2O2 is still quite toxic and can be mitigated by catalase.
Catalase aids in the removal of H2O2 by producing molecular O2 and H2O though its contribution
to overall cellular ROS mitigation has been a point of debate270–272. Glutathione is a tripeptide
that is able to utilize a cysteine residue thiol group to accept an electron and become reduced.
While multiple mechanisms exist to replenish the pool of oxidized glutathione, the GPx family
of proteins is able to oxidize glutathione and reduce H2O2 into H2O273,274. The expression and
activity of these enzymes can help to control the redox state and ROS protection of the cell 275.
6.Discussion In summary, this review has discussed: 1) various CVDs, prevalence, mortality
rates, and economic costs, 2) biochemical energetics, 3) mitochondrial genetics, 4) electron
transport, and 5) ROS production. It is clear how heart disease can be attributed to biochemical
alterations which are directly connected to the mitochondria. When the mitochondria become
stressed, electron transport can begin generating free radicals which cause a series of negative
chemical interactions involving DNA mutations. The proximity of ROS production inside of the
mitochondria can result it accumulated mtDNA mutations. Because each of the 13 proteins
encoded by mtDNA are paramount for proper electron transport, mutations can further propagate
stress on the mitochondria starting the cycle over.
6.1.Bioenergetics in heart failure During HF, carbon substrate utilization is altered in the
myocardium. The myocardial metabolic phenotype generally refers to the substrate and
metabolic preferences of the myocardium and is useful in comparing HF patient phenotypes to
healthy controls. The myocardial metabolic preferences are under the transient control of
circulating glucose, lactate, fatty acids, insulin, catecholamines, and oxygen concentrations as
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well as hemodynamics and inotropic state. The healthy heart generates the majority of energy
from fatty acids that seem to be maintained during earlier stages of HF; however, fatty acid
oxidation declines during end stage heart failure and shifts towards glycolytic substrates 276–279.
This is complicated, however, by age- and obesity-associated alterations in plasma FFA
concentrations and insulin sensitivity. While this makes one associate greater fatty acid oxidation
with healthy myocardia, cardiac lipotoxicity can occur by accumulation of triglycerides and
ceramides causing increased apoptosis and contractile decline280. This situation is further
complicated by an obesity paradox wherein obese patients are at greater risk to develop HF but
once diagnosed, obesity is associated with greater mortality compared to lean HF patients
especially following heart surgery281,282. This might be partly explained by other comorbidities in
lean HF patients, specifically cachexia or wasting syndromes which would categorize one as lean
but is associated with greatly reduced mortality.
6.2.Mitochondrial quality in heart disease Each of these processes, when working in concert,
can contribute to favorable mitochondrial quality. In cardiac disease, multiple dysfunctional
characteristics of mitochondrial quality are involved.
6.2.1.Dynamism and the heart Multiple studies have demonstrated that when balancing
fission/fusion of mitochondria, development of large, elongated organelles seems beneficial
when compared to small, fragmented mitochondria. In the heart, research demonstrates that
ischemic injury causes increased fission and fragmentation of mitochondria and that genetically
preventing fission to maintain a large, interconnected network improved cardiac outcomes 283–286.
But the case for fusion always being good and fission always being bad is more complicated,
however. Genetically enhancing mitochondrial fission through Drp1 does not negatively affect
cardiomyocyte function. Further, evidence in Drosophila melanogaster demonstrates that, while
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fission can remove damaged mitochondrial components, fusion can ‘poison’ the reticulum with
damaged components287. This is of severe detriment because the quick accumulation of mutated
mtDNA products that are not selectively removed and destroyed but rather propagate and create
mutated daughter organelles.
6.2.2.Mitophagy The process of mitophagy is inherently involved with mitochondrial dynamics
because the portion of mitochondria to be destroyed must first be separated. Deletion of PINK1
results in adolescent onset cardiomyopathy. While assessments of mitophagy were not done,
decreased respiratory function, overall mitochondrial quality and enlarged mitochondria were
seen287,288. Deletion of Parkin also increased the hearts sensitivity to MI and leads to
accumulation of damaged mitochondria with greater mtDNA mutations289,290. Similarly, genetic
ablation of BNIP3 or Nix lead to cardiac hypertrophy through decreased cardiac function and
abnormal mitochondria291,292. Overall, it would appear that too little or too much mitophagy
leads to heart disease so the key questions that remain involve the balance and timing of
mitophagic events. Genetically enhancing or limiting mitophagy over the lifespan of an organism
both lead to chronic heart failure. Specifically, chronic overactivation seems to deplete the pool
of healthy mitochondria contributing to oxidative deterioration while chronic lack of mitophagy
allows damaged organelles to accumulate and propagate. Following acute stressors, however,
such as MI or I/R, greater mitophagy allows enhanced clearance of damaged mitochondria to aid
in recovery293.
6.2.3.Biogenesis in heart disease If mitochondria are removed after ischemic damage, then the
pool of oxidative organelles must be replenished through biogenesis. Unfortunately, the shift
towards a ‘fetal gene program’ as seen in pathological cardiomyocytes decreases expression of
genes involved in fatty acid metabolism including PPARs and PGC-1α294. The activity of the
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TCA cycle as well as the contribution of β-oxidation-derived acetyl-CoA decreases at the end
stages of heart failure295. This could be an end result of decreased transcriptional machinery for
fatty acid oxidative. Studies have demonstrated that dilated cardiomyopathy is associated with
decreased expression of PGC-1α and decreased mtDNA copy number (a surrogate for the
amount of mitochondria) but no other markers for mitochondrial biogenesis were assessed296.
Some evidence has emerged suggesting a potential cardioprotective effect of PGC-1α but more
research is required to support these conclusions297. Others have reported impaired PGC-1α
expression during heart disease but no causal results were demonstrated298,299. However, on the
contrary, some approaches have demonstrated that PGC-1α can be detrimental to cardiac
function during disease300. These studies demonstrate the need for further assessment of the
coordination of mitochondrial biogenesis during heart disease.
6.3.Mitochondrial genetics and heart disease Multiple studies have shown a clear presence of
heart disease (specifically cardiomyopathy, dilated cardiomyopathy, and fatal infantile
cardiomyopathy) in patients with point mutations throughout the mitochondrial genome301–303.
These studies did not establish a causal relationship, however. It was also shown that in humans
with cardiomyopathies, gene expression of mitochondrial transcripts was elevated, perhaps to
compensate for inefficiencies within the OXPHOS system304. Overexpression of TFAM or
Twinkle can protect mtDNA, increase mtDNA copy number and contribute to cardioprotection
though it is unclear if this is due to replication or transcription mechanisms 122. Some
polymorphisms in the TFAM gene have also been linked to early MI 305. Wang et al.306
demonstrate that conditional TFAM knockout leads to early onset heart failure and dilated
cardiomyopathy suggesting that the mitochondrial gene expression machinery is requisite postnatally. Specific mtDNA mutations are highly associated with a variety of disease processes. The
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majority of diseases with mtDNA mutation are due to tRNA mutations likely because they are so
prevalent in the small mitochondrial genome and they will negatively affect each proteinencoding gene213. Mutations in mtDNA over the lifespan can also contribute to worsening MI or
I/R damage to cardiomyocytes307. In summary, it is clearly evident that mtDNA expression is
vital to cardiac health through the use of the mtDNA-encoded OXPHOS proteins. Any
alterations in global mtDNA expression (transcription/replication), global mtDNA mutations
(tRNAs), or specific protein mutations (any of the thirteen mtDNA-encoded proteins) can cause
or worsen heart disease and stress.
6.4.Electron transport and heart disease Studies have shown a clear presence of heart disease
(specifically cardiomyopathy, dilated cardiomyopathy, and fatal infantile cardiomyopathy) in
patients with point mutations of ETC complexes I, III, IV, and V as well as tRNA mutations and
large DNAa mutations301–303. However, these studies did not establish a causal relationship.
Inhibition of electron movement can help reduce components of the ETS during ischemia and
prevent reperfusion induced myocardial damage308,309. These results led to multiple studies
attempting to identify which complex of the ETC contributes to mitochondrial damage during
ischemia. Results have outlined that blockade of Complex I and III but not IV protect ischemic
injury. It is puzzling though because the authors suggest the ischemic injury is from some point
distal to complex III but proximal to complex IV with the only intermediary being cytochrome
C, a simple electron carrier310–313.
6.5.ROS and heart disease Under normal physiological conditions, the amount of ROS
produced by the cell is easily managed by ROS mitigation enzymes. During pathological
conditions such as chronic cardiomyopathies, alterations in normal electron transport function
can cause substantial increases in ROS production and cause cellular damage. Acutely, during
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ischemic episodes on the heart, the reintroduction of blood supply does not restore the hypoxic
organ but rather causes a reperfusion injury increasing substantial amounts of ROS,
inflammation, and apoptosis314. Indeed, aging related mutations in mtDNA contribute to
cardiomyopathy and this can be mitigated by overexpression of catalase 315. Mice lacking the
gene for MnSOD are perinatally lethal due to advanced cardiomyopathy269. Even in young drug
users, cocaine-induced cardiomyopathies have been attributed increased oxidative stress through
impaired redox handling in the heart 316. Current research is focusing on mitochondrionpermiable antioxidants to help mitigate ROS damage, especially following ischemia 317,318. While
ROS can act as a normal cell signaling molecule when controlled, the consensus of literature
suggests that overactive ROS production and impaired ROS handling are characteristics and
causes of heart disease319.
6.6.Conclusion In conclusion, the process of mt-mRNA translation is 1) vital to generate ETC
components is 2) indispensable for proper OXPHOS within the mitochondrion, 3) susceptible to
negative effects by ROS and mtDNA mutations, 4) can contribute to the oxidative capacity and
redox state of the cell and thus must be highly involved in heart disease. This leads to the
development of the following research aims:

Specific Aim I: Hypertrophic heart disease induced by aging and obesity alters the
machinery for mt-mRNA translation. Major cardiovascular disease is the leading cause of death
in the United States and is linked to obesity and aging. Chronic heart failure is associated with
fibrosis, systolic impairments, and reduced oxidative capacity leading to increased ROS
production. The reductions in oxidative capacity have been explained, in part, by decreased
electron transport through complexes I and IV of the ETC which contain a majority of subunits
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encoded by mtDNA and are created by mt-mRNA translation machinery. For experiments in this
aim, we will use a murine model of aging combined with obesity to induce cardiac hypertrophy.
Using primarily immunoblot, we will test if deteriorations in protein content of mt-mRNA
translation machinery could explain increases in ROS production and oxidative capacity seen in
cardiac muscle of aged, obese mice.
Specific Aim II: Pathophysiological cardiac atrophy is demonstrated with impaired mtmRNA translation machinery and shown to contribute to reduced oxidative capacity. Recently,
evidence has emerged of an atrophic state seen in the cardiac musculature of cancer patients.
This decrease in the myocardium has been associated with a decreased rate of protein synthesis
and an increase in protein degradation signaling. While a decrease in ventricular size may be
responsible for the relative increased incidence of heart failure among cancer patients, the
mitochondrial oxidative state and ROS mitigation may play a critical role. Using LLC tumor
implantation in mice, we will induce cardiac atrophy and use immunoblot procedures to
determine if mitochondrial content, ROS mitigation, and mt-mRNA translation machinery are
altered in a mouse model cancer-induced cardiac atrophy.
Specific Aim III: mt-mRNA translation initiation is required for maintenance of oxidative
potential and oxidation-reduction state. Oxidative capacity requires appropriate mitochondrial
ETC components which are necessary for appropriate oxidative phosphorylation without excess
production of ROS. While chronic heart disease and the associated production of ROS is partly
due to reduced capacity for ROS mitigation, the potential exists for reduced efficiency of mtmRNA translation to result in both impaired oxidative capacity and increased production of
ROS, simultaneously. Using cardiomyocytes in vitro, we will genetically inhibit mtIF2 mRNA
and examine metabolic oxidative flux and redox characteristics. These experiments will help
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determine how mtIF2 contributes to mt-mRNA translation as a candidate protein responsible for
the detriments in ETC components, subsequent decrements in oxidative capacity and redox state
of cardiac muscle cells.
These experiments will demonstrate that mt-mRNA translation is required for oxidative
metabolism and control of harmful ROS production. I have compiled these aims into two
manuscripts based on the congruency of the results. Experiments from Aim II are presented in
manuscript 1 entitled, “Cancer-induced Cardiac Atrophy Adversely Affects Myocardial Redox
State and Mitochondrial Oxidative Capacity”. Aims I and III have been combined in manuscript
2 entitled, “Mitochondrial Translation Initiation Factor 2 is Necessary for Cardiac Oxidative
Capacity as Evident during Age-induced Cardiac Hypertrophy”.
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Abstract: Cachexia presents in nearly 80% of advanced cancer patients; however, cardiac
atrophy in cachectic patients has received little attention. This unique form of cardiomyopathy in
cancer patients contributes to increased occurrence of myocardial ischemia and adverse cardiac
events compared to age-matched population norms. Research on cardiac atrophy has focused on
cardiac remodeling; however, alterations in oxidative metabolic properties may be a significant
contributor to this form of cardiac disease. Purpose: To determine how cancer-induced cardiac
atrophy alters in-vivo mitochondrial turnover, mitochondrial mRNA translation machinery, ROS
scavenging and in-vitro oxidative characteristics. Methods: PBS or Lewis lung carcinoma (LLC)
tumors were implanted in mice and grown for 28 days to induce cardiac atrophy. Hearts were
examined for endogenous optical metabolic species, and immunoblotted to assess markers of
mitochondrial function. H9c2 cardiomyocytes were cultured in a control media or media
collected from LLC cells in combination with a mitochondrially-targeted antioxidant
(MitoTempo). Cells were analyzed for production of ROS, oxidative capacity, and resistance to
hypoxic stress. Results: LLC hearts demonstrated ~15% lower optical redox ratio
(FAD/FAD+NADH) indicating greater glycolytic reliance compared to PBS controls. When
compared to PBS, LLC hearts showed ~50% greater mitochondrial content markers (COX-IV,
VDAC) attributed to ~50% lower PINK1/Parkin-mediated mitophagy markers while
mitochondrial protein synthesis and biogenic proteins PGC-1α, PPARα, and PPARδ were not
different. Mitochondrial mRNA translation machinery was unchanged between groups relative to
amount of mitochondria. Mitochondrial DNA-encoded CytB was ~30% lower in LLC hearts
suggesting impairments in outcomes of mitochondrial mRNA translation. ROS scavengers GPx3 and GPx-7 were ~50% lower in LLC hearts. Treatment of cardiomyocytes with LLCconditioned media resulted in higher ROS (25%), lower oxygen consumption rates (10% at
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basal, 75% at maximal), and greater susceptibility to hypoxic-insult by ~25% -- all of which
were reversed by addition of MitoTempo. Conclusion: These results substantiate metabolic
cardiotoxic effects attributable to tumor-associated factors and provide new insight into
interactions between mitochondrial mRNA translation, ROS mitigation, oxidative capacity and
hypoxia resistance.
Graphical Abstract:

Control

____FAD___
(FAD +
NADH)

Cancer-Induced Cardiac
Atrophy

____FAD___
(FAD + NADH)

Figure: Graphical abstract outlining the key findings of this publication.

Highlights:


Cancer leads to altered metabolism and atrophy of the heart



Mitochondrial turnover, mRNA translation, and ROS scavenging are all affected



Mitochondrial ROS scavengers protect aerobic capacity and hypoxia resistance



Antioxidant drugs mitigate the effects of tumor-associated changes to the heart
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Keywords: Cardiac cachexia, optical redox imaging, mitochondrial translation, cardiac wasting,
cardio-oncology, mitochondrial antioxidant




Abbreviations: COX-IV – cytochrome oxidase subunit IV, CytB – mitochondrial-encoded Cytochrome B1, FAD –
Flavin adenine dinucleotide, GPx – Glutathione peroxidase, HIF-1α – Hypoxia-inducible factor 1α, LLC – Lewis
Lung Carcinoma, mtIF2/3 – mitochondrial translation initiation factors 2/3, mtDNA – mitochondrial-encoded DNA,
mt-mRNA – mitochondrial-encoded mRNA, NADH – nicotinamide adenine dinucleotie, nDNA – nuclear encoded
DNA, PBS – Phosphate-buffered saline, PGC-1α – PPARγ co-activator-1α, PPARα/δ – Peroxisome proliferatoractivated receptor α/δ, OXPHOS – Oxidative phosphorylation system, Redox – oxidation/reduction, ROS – Reactive
Oxygen Species, SOD – Superoxide dismutase, TACO1 – Translational co-activator of COX1, TFAM –
mitochondrial transcription factor A, TPEF – Two-photon excitation fluorescence, VDAC – voltage-dependent
anion channel
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Introduction
Cancer cachexia is a progressive deterioration of functional capacity characterized
predominantly by a loss of skeletal muscle mass with impacts on multiple other organs 1. While
cachexia is present in as many as 80% of advanced cancer patients2, the comorbidity of cardiac
atrophy in cachectic patients has received little attention3. The clinical focus in targeting the
underlying malignancy often dismisses cardiotoxic effects of radiation and chemotherapeutic
treatment approaches4,5. However, recent data demonstrates that advanced cancer contributes to
detrimental cardiac alterations including reduced left ventricular systolic function and decreased
cardiac musculature resulting from tumor-derived factors rather than from
chemo/radiotherapies6,7. While the compounding effects of tumor-related cardiac alterations,
treatment modalities, and potential of underlying heart disease make it difficult to determine the
etiology of cardiac atrophy seen in cancer patients5, further research is desperately needed to
understand how cancer contributes to changes in the cardiac metabolic state.
Heart failure has been tightly linked to alterations in metabolic substrate utilization and
detriments to mitochondrial oxidative capacity8,9. Specifically, patients with heart disease exhibit
a shift from fatty acid oxidation towards greater reliance on glucose as a source for ATP 10.
Mitochondria have therefore become a key target in combatting this metabolic reprogramming in
heart disease as these organelles contribute ~90% of ATP generated in the healthy
myocardium11–13. Previous research supports these efforts to target mitochondria because
electron transport through oxidative phosphorylation (OXPHOS) complexes I and III limits
oxygen flux during left ventricular systolic dysfunction14. When electron transport at these
specific OXPHOS sites decreases, they can become primary producers of reactive oxygen
species (ROS)15. These free radicals, when left unmitigated16, can contribute to DNA mutations
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and damage, protein modifications, and membrane lipid oxidation17–23. Because of the proximity
to mitochondrial DNA (mtDNA), ROS produced at OXPHOS complexes has the potential to
mutate mtDNA and further contribute to detriments in OXPHOS electron transport seen in heart
failure24. This interconnected relationship between mtDNA mutations, OXPHOS deficits, and
ROS production provides the basis for Harman’s free radical theory of aging 25 and more
specifically, the mitochondrial theory of heart disease26. While progressive loss of mtDNA copy
number, increased mtDNA mutations27,28, OXPHOS deterioration14, and excess ROS29 are well
established contributors to traditional cardiomyopathies, the mitochondrial alterations during
cancer-induced cardiac atrophy remain unclear.
Key to elucidating mitochondrial bioenergetics during cancer-induced cardiac atrophy is
understanding the processes of mitochondrial turnover and maintenance of OXPHOS complex
activity. The balance of mitochondrial biogenesis and mitophagy contribute to fluctuations in
organelle volume within the myocardium, however, mitochondrial mRNA(mt-mRNA)
translation machinery likewise contributes to OXPHOS activity and proper electron transport 30–
35

. A balance between mt-mRNA translation and cytoplasmic translation is required for proper

assembly of OXPHOS complexes36 and during situations of impaired mt-mRNA translation,
metabolic side-effects are evident 37–39. Improper translational insertion40 by mt-mRNA
translation machinery also contributes to ROS production and alters antioxidant defenses through
the mitochondrial unfolded protein response41,42. The connection between mt-mRNA translation
and cardiomyocyte oxidative capacity has not been well established 43,44.
In an effort to better understand the impact of cancer-induced cardiac atrophy on
mitochondrial oxidative characteristics, the purpose of this investigation was to examine
mitochondrial turnover and mt-mRNA translation alterations during this unique form of heart

91

disease. Furthermore, we investigated tumor-associated changes in antioxidant defense as a
mechanism of excess ROS production and how this contributes to the deleterious effects on
cardiac oxidative reserve capacity and resistance to hypoxia. By using an established, in-vivo
model of cancer-induced cardiac atrophy we present label-free metabolic oxidation-reduction
(redox) characteristics indicative of heart disease, alterations in mitochondrial content, mtmRNA translation, and ROS scavengers. We further demonstrate the potential efficacy of
mitochondrially-targeted antioxidants to mitigate excessive ROS production and how this
approach protects against hypoxic insult to cardiomyocytes in-vitro.
Materials and Methods
Animal model of cancer-induced cardiac atrophy
All methods were approved by the Institutional Animal Care and Use Committee at the
University of Arkansas. C57BL6/J mice were injected with 1x106 Lewis Lung Carcinoma cells
(LLC) or equal volume sterile phosphate-buffered saline (PBS) as previously described45,46. LLC
cells were purchased from American Type Culture Collection (ATCC, CRL-1642) and grown in
DMEM containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (pen/strep)
with media changed every second day. Cells were trypsinized, centrifuged, and counted prior to
implantation. Tumors were allowed to grow for 28 days before mice were euthanized and hearts
excised. Multiple small sections of the left ventricle were separated to allow protein and
histological assessment of the same sample. Heart samples were snap frozen and stored at -80oC
before further analysis. Mice were injected with 99.9% 2H2O in the peritoneum (20μL/g body
weight, Sigma-Aldrich, St. Louis, MO, USA) 24 hours prior to euthanasia. 4% 2H2O in H2O
(v/v) was provided as drinking water ad libitum for the entire 24 hour period as previously
described47.
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Two-photon excitation fluorescence of endogenous NADH and FAD
Two-photon excitation fluorescence (TPEF) was used to measure endogenous
fluorescence of NADH and FAD as previously described48. Briefly, laser excitation by MaiTai
Ti:Sapphire laser source (Spectra-Physics, Santa Clara CA) was tuned to 755nm or 860nm.
Images were acquired using a resonant-galvo scanner and GaAsP photomultipler tubes (H742240, Hamamatsu) with 460/40nm (NADH), 525/45nm (FAD), and 600/70nm (Rhodamine) filters.
10μm section of the left ventricle were cut along the short axis. Slides were imaged (512x512
pixels, 16bit depth, 260μm2) and the pixel-wise FAD/(NADH+FAD) ratio normalized to
rhodamine was calculated. Multiple fields were imaged for each sample and averaged to
represent an individual biological sample. NADH and FAD image analysis was completed using
MATLAB (MathWorks, Natick, MA).
Immunoblot analysis
Protein was extracted from small fractions of muscle taken directly from the left
ventricle, separated by 8% or 12% SDS-PAGE and transferred to polyvinylidene fluoride
membrane as described49,50 alongside a molecular weight ladder. Membranes were blocked
using 5% milk in TBS (w/v) with 0.2% tween and incubated with specific primary antibodies at
4°C overnight. Primary antibodies were specific to HIF-1α (NB100-105, Novus Biologicals),
COX-IV (Cell Signaling 4855S) VDAC (Cell Signaling, 4866S), PGC-1α (Santa Cruz sc13067), PPARα (Santa Cruz sc-9000), PPARδ (Santa Cruz sc-7197), BNIP3 (Cell Signaling
3769), PINK-1 (Santa Cruz sc-33796), Parkin (Cell Signaling 42115), pSer65-Parkin (Abcam
ab154995), mtIF2 (Santa Cruz sc-365477), mtIF3 (Origene TA800421), TACO1 (Abcam
ab121688), CytB (Santa Cruz 11436), Total OXPHOS antibody cocktail (Abcam ab110413,
Complex I – NDUFB8, Complex II – SDHB, Complex III – UQCRC2, Complex IV – MTCO1,
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Complex V – ATP5A), SOD1 (Genetex GTX100554), SOD2 (Cell Signaling 131945), SOD3 (R
and D Systems AF4817), GPx7 (Genetex GTX117516), GPx3 (Genetex GTX89142), and
Catalase (Cell Signaling 140975). Using appropriate HRP-conjugated or fluorescent conjugated
secondary antibodies, protein antigens were visualized within a linear range by either ECL on
Protein Simple FluorChemM (Minneapolis, MN) or near-infrared fluorescence on Odyssey Fc
(LI-COR, Lincoln, NE) and analyzed using ImageStudio Software (LI-COR). Bands were
normalized to the 45kDa Actin band of PonceauS as loading control. For each experiment, all
groups were represented on each membrane and normalized to control.
Mitochondrial Isolation and 24-hour Protein Synthesis
Isolation of mitochondrial subpopulations and fractional synthesis rates were determined
from samples as previously described (34). Briefly, 30 mg of left ventricle was homogenized
isolation buffer 1 (10 mM HEPES, 20 mM sucrose, 50 mN mannitol, 2mM EDTA, 0.25% v/v
protease inhibitor cocktail, pH 7.4) and centrifuged at 650 x G. The supernatant was then further
centrifuged at 10,000 x G for 10 minutes and pellet collected for analysis of subsarcolemmal
(SS) mitochondria. SS mitochondria were washed in isolation buffer 2 (50 mM HEPES, 5mM
EGTA, 1mM ATP, 100mMKCL, 5 mM MgSO4, 0.25% v/v protease inhibitor cocktail, pH 7.4)
The intermyofibrillar (IMF) mitochondria were separated from the myofibrils in pellet created in
the first centrifugation first by dounce homogenization in isolation buffer 3 (100 mM KCl, 50
mM Tris, 5 mM MgCl2, 1 mM EDTA, 10 mM Beta-glycerophosphate, 1.5% w/v BSA, 0.25%
v/v protease inhibitor cocktail, pH 7.5). The resulting homogenate was centrifuged at 650 x G
and the resulting supernatant was centrifuged at 10,000 x G for 10 minutes and mitochondrialrich pellet collected. SS and IMF proteins were hydrolyzed into individual amino acids by
heating for 24 hours at 100°C in 6N HCl. An aliquot of the hydrolysate was dried down and

94

mixed with a 3:2:1 solution of methyl-8, methanol, and acetonitrile to determine 2H-labeling of
alanine on its methyl-8 derivative. The solution was then placed in a GC-MS and analyzed for
the ratio of labeled alanine to unlabeled alanine was used to calculate protein synthesis. In order
to normalize results based on the precursor pool of 2H2O, plasma was reacted with 10 M NaOH
and a 5% solution of acetone in acetonitrile for 24 h in order to conjugate the free 2H2O to
acetone. The solution was extracted by adding Na2SO4 and chloroform, and analyzed on the
GCMS. FSR of proteins was calculated using the equation EA × [EBW × 3.7 × t (h)]−1 × 100,
where EA represents amount of protein-bound [2H]alanine (mole% excess), EBW is the quantity
of 2H2O in body water (mole% excess), 3.7 represents the exchange of 2H between body water
and alanine (3.7 of 4 carbon-bound hydrogens of alanine exchange with water) and t(h)
represents the time the label was present in hours.
H9c2 Culture experiments
H9c2 ventricular cardiomyocytes were purchased from ATCC (CRL-1446) and grown at
370C, 5%CO2, and 20% O2 in DMEM containing 10% FBS and 1% pen/strep (GM) and changed
every second day. When cells were ~75% confluent, 2x104 cells/well were sub-cultured in 96well plates for 24 hours before media was replaced with control media (CM; DMEM containing
2.5% FBS, 1% pen/strep) or LLC-conditioned media (LCM) as previously described51,52. To
generate LCM, LLC growth media was collected after two days of incubation in 162cm2 flask
with LLC density ending ~75% confluence. Media was centrifuged and filtered to remove cells
and cell debris and diluted 1:4 (v/v) with serum-free DMEM. MitoTEMPO (MitoT; SML0737,
Sigma-Aldrich, St. Louis, MO) diluted in PBS was added to CM or LCM at a concentration of 2
μM. After 2 hours incubation in respective media, 5μM MitoSOX Red (M36008, Invitrogen) in
PBS was added to cells for 10 minutes, rinsed, and cells were visualized at 510/580nm (ex/em)

95

on Nikon TiS epifluorescent microscope (Melville, NY) to assess mitochondrial superoxide
production.
Bioenergetic flux analysis
Oxygen consumption rates (OCR) were analyzed using Seahorse XFp extracellular flux
analyzer (Agilent, Santa Clara, CA) according to manufacturer instructions and as previously
described53. Briefly, 2x104 cells were seeded per well in GM. After 24 hours, media was
removed, cells were rinsed with sterile PBS, and replaced with CM or LCM with or without 2
μM MitoT. After 24 hours incubation, media was removed and replaced with Seahorse Assay
media containing 7 mM glucose, 2 mM pyruvate, and 2 mM glutamine. OCR was measured
prior to and following sequential addition of 1 μM oligomycin, 1 μM FCCP, and 1 μM
rotenone/Antimycin A. This allowed assessment of cellular OCR related to basal respiration and
maximal uncoupled respiration. Reserve respiration was determined as the difference between
maximal and basal after normalizing to non-mitochondrial oxygen consumption.
Hypoxic exposure and MTT viability assessment
In order to assess the resistance of H9c2 cells to hypoxic challenge, 2x10 4 cells/well were
plated in 96-well plate and incubated in GM for 24 hours. Media was replaced with CM or LCM
with or without 2 μM MitoT. After 24 hours incubation at 5% CO 2 and 20% O2, media was
replaced with serum-free DMEM and cells were placed in a dual gas controlled (Oxycycler C42,
Biospherix, Parish, NY) incubator sub-chamber. Oxygen was flushed by nitrogen and maintained
at 1% O2 and 5% CO2 for 6 hours. The combination of serum-free media with a hypoxic
environment was used to simulate ischemic conditions54. Following hypoxic exposure, 1 mM
MTT (M6494, Invitrogen) was added to cells and incubated ~21% O 2 for 2 hours. The resulting
formazan crystals were solubilized by addition of 100 μL of 350 mM SDS in 0.01% HCl and
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absorbance was read at 570 nm. A separate plate was maintained at ~21% O2 to serve as 100%
viability control.
Statistical Analysis
Statistics were calculated and visualized using GraphPad Prism v6.0. To compare PBS to
LLC groups, Student’s t-test was used with α set at 0.05. For cell culture experiments, a 2x2
ANOVA was used to compare main effects or interactions between groups (CM x LCM vs.
Control x MitoT). Where significant omnibus differences occurred, Tukey’s post-hoc analysis
was used to investigate changes within groups. Cell culture experiments were analyzed using 3
biological replicates and at least 3 technical replicates. Data presented represent mean ± SEM.
Results and Discussion
Cancer cachexia contributes to cardiac atrophy and altered optical metabolic properties
Four weeks of LLC tumor implantation resulted in severe skeletal muscle and fat mass loss
including a ~30% reduction in muscle cross-sectional area as we previously reported in the same
animals demonstrating cancer cachexia in this model45,46. In the current study, we used the same
animal cohort to analyze cardiac alterations associated with tumor implantation45,46. Total wet
weight of the heart was 10% lower in LLC compared to PBS demonstrating atrophy of the
myocardium (p < 0.01, Table 1). Tibia lengths were not different between experimental
conditions suggesting body size was similar between groups so we have presented raw heart
mass.
To further characterize the metabolic alterations associated with this form of cardiac
atrophy, we performed TPEF of endogenous FAD and NADH. This approach has demonstrated
to be a powerful, label-free assessment of metabolic characteristics in a variety of cell and tissue
types53,55–58. TPEF is a powerful new technique to identify metabolic intermediates in a label-free
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assessment of cellular metabolic state59. In calculating the optical redox ratio, we identified a
significantly lower redox ratio in LLC heart samples compared to PBS (Figure 1A, B; mean of
0.75 in PBS vs. 0.68 in LLC, p < 0.01). A lower optical redox ratio is indicative of less
utilization of mitochondrial oxidative metabolism and greater reliance on glucose 56.
Additionally, immunoblot analysis of HIF-1α indicates ~100% greater content in LLC compared
to PBS (Figure 1C). HIF-1α is a key sensor of oxygen levels and can downregulate
mitochondrial oxidative metabolism while promoting glycolytic enzymes; a characteristic of
cardiomyopathy metabolic changes60,61. These results extend upon previous evidence of showing
decreased heart size in colorectal cancer-induced cardiac atrophy62 and the shift away from βoxidation towards glycolysis seen in heart failure8.
Cardiac atrophy disrupts mitochondrial clearance
Mitochondrial function has been a target for heart failure treatments to combat against the
metabolic shift that occurs13; therefore, we analyzed proteins associated with mitochondrial
content and biogenesis. Both COX-IV and VDAC levels were significantly greater in LLC
compared to PBS by ~40% and ~75%, respectively (Figure 2B, p < 0.05) indicating elevated
mitochondrial content in LLC hearts. There were no differences measured between experimental
groups in subsarcolemmal or intermyofibrillar mitochondria fractional synthetic rates nor in
protein content of regulators of mitochondrial biogenesis including PGC-1α, PPARα, or PPARδ
(Figure 2B,C; p > 0.05). In other models of heart failure, downregulation of proteins associated
with lipid metabolism including PPARα and PGC-1α as well as respiratory-chain complex
activity has been reported63. However, electron microscopy reveals that the amount of
mitochondria are increased in many forms of cardiomyopathy despite other structural
malformations64. Greater mitochondrial content (COX-IV, VDAC) absent upregulation of
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mitochondrial biogenesis (i.e. mitochondrial FSR, PPARs, PGC-1α) suggests alternate processes
contributing to the overall mitochondria pool. Total mitochondrial content is a highly regulated
balance between biogenesis and mitochondrial-specific autophagy (mitophagy)30, thus an
imbalance in mitochondrial content between PBS and LLC with no alteration in biogenesis
predicates mitophagy as a contributing factor. This led us to examine markers of two common
mitophagic pathways, BNIP3 and PINK1/Parkin. Protein content of BNIP3 was unchanged
between PBS and LLC hearts (p > 0.05) while the total content of PINK1 and the ratio of
phosphorylated to total Parkin were both decreased by ~50% (Figure 3; p < 0.05). These markers
indicate PINK1/Parkin mediated mitophagy detriments may contribute to a build-up of
(presumably) defective mitochondria which has, as yet, remained unclear during chronic heart
disease31. Parkin-deficient mouse models present with accumulation of depolarized mitochondria
following myocardial infarction indicating the importance of this pathway in the clearance of
these damaged organelles in the myocardium65. These results suggest an important role for
Parkin-dependent mitochondrial clearance in cancer-induced cardiomyopathies which could
result in accumulation of depolarized mitochondria. The consequences of depolarized
mitochondria that are not efficiently broken down in the myocardium remains uncertain.
LLC myocardial mt-mRNA translation machinery is unable to maintain mtDNA-encoded
OXPHOS subunits
mt-mRNA translation machinery allows proper translation of 13 protein subunits encoded
by mt-DNA which are required for proper production of core portions of OXPHOS complexes 34.
TFAM is a key factor involved in mtDNA transcription66 and the primary controllers of mtmRNA translation are two mammalian mitochondrial initiation factors mtIF2 and mtIF3 67.
Additionally, co-translational insertion using translational coactivators – such as TACO1 in
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mammals – is required for proper assembly of OXPHOS complexes40. These factors work to
create a balance between mt-mRNA translation and cytoplasmic translation to produce and
assemble OXPHOS complexes in a manner that optimizes electron transport and ATP
production36. TFAM, mtIF2, mtIF3, and TACO1 protein contents were all significantly higher in
LLC compared to PBS by ~50-125% (p < 0.05). However, the mt-mRNA translation product
CytB was not significantly altered by the LLC tumor (Figure 4A; p > 0.05). To assess content of
proteins relative to the total mitochondrial pool, we normalized mt-mRNA translation proteins to
VDAC protein. We observed no differences seen in TFAM, mtIF2, mtIF3, or TACO1 between
experimental groups (p > 0.05); however, CytB, when normalized to VDAC as a marker of
mitochondrial content, was ~45% lower in LLC compared to PBS (Figure 4B; p < 0.05). When
complex content was assessed using immunoblot analysis of individual core subunits, we found
no significant difference between groups for Complex I, III, or V (p > 0.05) but found
significantly elevated content of Complexes II and III (Figure 4C ,p < 0.05). The proteins
encoded by mtDNA are integral, core subunits in OXPHOS complexes I, III, IV, and V 34. In
each complex, the mtDNA-encoded channels are vital for appropriate electron transport or
proton translocation across the membrane68. Where mutations or alterations in expression of
mtDNA-encoded proteins arise, oxidative complications associated with cardiac illness are
evident19,24. The results presented here suggest that during this form of cardiomyopathy, the
machinery responsible for expression of mtDNA-encoded transcripts is maintained relative to the
mitochondrial content as measured by VDAC. However, resulting mtDNA-encoded protein
subunits of OXPHOS may not be equally maintained suggesting other possible issues
responsible for deficient mitochondria-encoded protein expression. By assessing amount of
complex formation through immunoblot of subunits that are labile when not assembled, we
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found that complexes with a large proportion of mtDNA-encoded proteins were no different
between groups (Complex I, IV, V) while those with primarily nDNA-encoded portions
(Complex II, III) were elevated concomitant with mitochondrial content markers. This reduced
content of mtDNA-encoded proteins can result in misincorporation of OXPHOS subunits and
prevent efficient electron flow through complexes I and III and result in greater production of
superoxide, presumably through reverse electron transport 69. Mitigation of free radicals by
antioxidant enzymes may present as a potential mechanism to protect against excessive ROS
produced during heart disease29.
LLC contributes to altered ROS scavenger protein levels
In an effort to better understand handling of ROS, we assessed various proteins involved in
superoxide (superoxide dismutases: SOD1, 2, 3) and hydrogen peroxide dissipation (Catalase,
Glutathione Peroxidases: GPx-3,7). No differences in protein content of SOD-1, 2, or 3 were
found between PBS and LLC hearts (Figure 5A; p > 0.05). Protein content of Catalase was 80%
more abundant in LLC animals compared to PBS (p < 0.05), while GPx-3 and GPx-7 were both
significantly lower in LLC compared to PBS by ~60% (p < 0.01) and ~50% (Figure 5B; p <
0.05), respectively. Taken together, these results suggest no alterations in the control of
superoxide radicals through dismutase proteins. However, alterations appear in proteins involved
in hydrogen peroxide (H2O2) clearance. Specifically, the elevation seen in Catalase content was
unexpected because, previously, elevated Catalase has been linked to mitigation of agedependent heart disease in mice70. The levels of GPx-3 and -7 were both reduced by the tumorassociated cardiomyopathy. Taken together, this could signify an overall decrease in ability to
handle H2O2 because GPx’s maintain greater affinity for 71 and reactivity with H2O2 compared to
catalase at physiologically relevant concentrations72. Excessive H2O2 has been seen in aging-
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induced heart disease despite greater activity of Catalase73, which may contribute to cardiac cell
death74 and reduced mitochondrial oxygen consumption75. While direct measurements of ROS
production and OCR were not assessed in PBS and LLC hearts, we next sought to determine
how tumor-associated factors could alter mitochondrial ROS production and OCR in cardiac
cells in-vitro.
Mitochondrial antioxidants mitigate effects of tumor-associated factors on cardiomyocyte ROS
production and oxidative capacity
To directly assess impacts of tumor-associated factors on the myocardium, independent
of circulating factors (immune cells, compliment), cardiomyocytes were cultured in CM or LCM
alone or in combination with MitoT, a mitochondria-targeted antioxidant. Two hours following
treatment, ROS accumulation was assessed using MitoSOX fluorescence. H9c2 cardiomyocytes
showed ~25% greater MitoSOX fluorescence when incubated in LCM alone (p < 0.001). The
combination with MitoT had no effect on MitoSOX in CM-treated cells (p > 0.05), however,
combined LCM and MitoT treatment showed significantly lower MitoSOX fluorescence
compared to LCM alone (p < 0.001) to the point that LCM + MitoT was not different compared
to CM (Figure 6A, B; p > 0.05). To further test the detrimental effects of LCM, cardiomyocytes
were treated for 24 hours and oxygen flux analysis was assessed (Figure 6C). Basal OCR was
~15% lower following 24 hours of LCM treatment compared to CM (p < 0.01) with no effects of
MitoT on LCM treated cells (Figure 6D; p > 0.05). When cells were treated with FCCP to
simulate maximal OCR rates, LCM control cells had a maximal OCR that was ~1/3 that of the
CM (p < 0.01). When combining LCM with MitoT, maximal OCR was higher than LCM control
(p < 0.01) and not different from either CM treatment (Figure 6E; p > 0.05). Using these values,
we were able to calculate the reserve OCR which followed a similar pattern of severe reduction
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(~75% capacity) relative to CM following 24 hours LCM (p < 0.01) but not when combined with
MitoT (Figure 6F; p > 0.05). These results demonstrate a clear connection between tumorassociated factors and alterations in mitochondrial metabolic characteristics in cardiac muscle
cells. The initial increases in ROS production following LCM treatment can be mitigated using a
mitochondrial antioxidant and overtime can result in functional rescue of mitochondrial
oxidative reserve. One way myocardial oxidative capacity contributes to cardioprotection is
through resistance to hypoxic-insult76–78. In order to test if our results in OCR reflected
susceptibility to hypoxia-induced cell death, we exposed cells to 1% O2 for 6 hours and assessed
cell viability. All groups demonstrated significantly lower viability following hypoxia compared
to normoxic control (dashed line) with LCM control being significantly lower compared to CM
and LCM + MitoT cells by ~30% (Figure 7A; p < 0.001). These data suggest that cancer-induced
oxidative alterations may be rescued through mitigation of mitochondrial ROS. There is
considerable need to better characterize the oxidative metabolic properties of the myocardium
undergoing cancer-induced structural alterations. These results substantiate cardiotoxic effects
attributable to tumor-associated factors and provide new insight into interactions between ROS
mitigation, cardiac oxidation and hypoxia resistance.
Our findings suggest cancer-induced cardiac atrophy presents with altered metabolic
properties associated with heart disease including greater reliance on glycolysis assessed using a
label free measurement of endogenous redox species and elevation in HIF-1α. We additionally
present impaired mitochondrial clearance, disruptions in mt-encoded protein expression, and less
protein involved in ROS mitigation. Finally, in-vitro experiments show that tumor-specific
factors exacerbate cardiac ROS production, lead to detriments in oxidative reserve, and enhanced
susceptibility to hypoxic challenge – all of which can be reversed using mitochondria targeted
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antioxidants. The results presented here extend previous research (focused specifically on cardiac
remodeling) by demonstrating metabolic and mitochondrial alterations in this unique form of
heart disease. Maintenance of mitochondrial oxidative function is key in tailoring therapeutic
approaches to limit cardiotoxic effects in treating the primary malignancy as well as limiting
tumor-specific cardiomyopathy (Figure 7B). This is paramount in a clinical setting because
cancer patients have increased occurrence of both myocardial ischemia 79 and adverse cardiac
events80 compared to age-matched population norms. We now provide evidence for the utility of
mitochondrial antioxidants to combat cancer-induced oxidative impairments in the myocardium.
Others have attempted to use pharmaceutical approaches to treat excessive ROS production in
heart disease81–83 but present with adverse effects on physiological ROS signaling in multiple
other systems84. Our results suggest two pathways involved in pathological accumulation of free
radicals through 1) loss of functional expression of mt-mRNA translation products for OXPHOS
and 2) downregulation of GPx proteins for H2O2 clearance. An alternative approach to combat
excess ROS may be utilizing alternative pharmaceuticals which could indirectly reduce
myocardial ROS85.
Conclusion
In summary, we present evidence of mitochondrial alterations contributing to ROS generation
during cancer-induced cardiac atrophy in-vivo. We build on these results by demonstrating
factors produced by the tumor cells contribute to reduction in cardiomyocyte oxidative reserve
in-vitro. With heart disease and cancer competing for the leading cause of mortality worldwide,
the contribution of malignancy to cardiomyopathy must be made clear and approaches to
mitigate it researched. Further research should focus on the compounding effects of cancer and
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chemotherapeutics on cardiac function and how other cancers less associated with cachexia may
still contribute to heart disease.
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Table 1. Descriptive statistics of heart weight.
Heart wet weight (mg)
PBS

120.08±3.15

LLC
108.21±3.36*
Data represent M±SEM. * - p < 0.05 compared to PBS.
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Figure 1. Cancer-induced cardiac atrophy demonstrates metabolic characteristics of heart
disease. (A) Representative images of FAD, NADH, and redox ratio of TPEF of endogenous
redox species within the myocardium of PBS and LLC left ventricle sections. (B) Calculated
optical redox ratio and (C) HIF-1α protein content of PBS and LLC hearts. * indicates p < 0.05.
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Figure 2. Cancer-induced cardiac atrophy alters mitochondrial content markers but not
mitochondrial biogenesis protein content. (A) Markers of mitochondrial content, (B)
subsarcolemmal and intermyofibrillar mitochondral FSRs and (C) markers of mitochondrial
biogenesis in PBS and LLC hearts. (D) Sample immunoblot images of protein target indicated.
Bands were cropped at indicated molecular weight and to show each group side-by-side. *
indicates p < 0.05.
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Figure 3. (A) Cancer-induced cardiac atrophy disrupts mitochondrial clearance. Markers of
mitochondrial autophagy BNIP3, PINK, and phosphorylated to total Parkin in PBS and LLC
hearts. (B) Sample immunoblot images of protein target indicated. Bands were cropped at
indicated molecular weight and to show each group side-by-side. * indicates p < 0.05.
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Figure 4. Cancer-induced cardiac atrophy disrupts mt-mRNA translation products but not mtmRNA translation machinery. (A) Mitochondrial transcription and translation machinery
(TFAM, mtIF2, mtIF3, TACO1) and a mt-mRNA translation product (CytB) normalized to total
protein content by PonceauS and (B) normalized to mitochondrial content marker COX-IV in
PBS and LLC hearts. (C) Immunoblot analysis of OXPHOS complex content as determined
through protein subunits required for complex formation. Specific target for each subunit is
indicated in the materials and methods section. (D) Sample immunoblot images of protein target
indicated. Bands were cropped at indicated molecular weight and to show each group side-byside. * indicates p < 0.05.
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Figure 5. Cancer-induced cardiac atrophy disrupts hydrogen peroxide clearance protein content.
(A) Superoxide dismutase protein isoforms and (B) hydrogen peroxide mitigation proteins
catalase, and glutathione peroxidases -3 and -7 in PBS and LLC hearts. (C) Sample immunoblot
images of protein target indicated. Bands were cropped at indicated molecular weight and to
show each group side-by-side. * indicates p < 0.05
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Figure 6. Media from LLC cancer cells contribute to greater ROS and reduced oxidative
capacity. H9c2 cells were treated with a combination of LLC media (LCM) and 2μM of the
mitochondrial targeted antioxidant (MitoT) for 2 hours and ROS assessed using MitoSOX (A,B)
or similar treatment for 24 hours analyzing cellular bioenergetic flux analysis (C) to analyze
oxygen consumption rates at (D) basal and (E) maximal rates, or calculated reserve rates (F).
Scale bar = 100μm. * indicated p < 0.05 vs. control media (CM) with no MitoT (con); †
indicated p < 0.05 vs. con cells receiving same media condition.
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Figure 7. Media from LLC cancer cells reduces resistance to hypoxic insult in cardiomyocytes.
(A) H9c2 cells were treated with a combination of LLC media (LCM) and 2μM of the
mitochondrial targeted antioxidant (MitoT) for 24 hours and exposed to 1% oxygen and serumfree media for 6 hours followed by MTT viability assessment. * indicates p < 0.05 vs. control
media (CM) with no MitoT (con); † indicates p < 0.05 vs. con cells receiving same media
condition; dashed line at 100% indicates control cells that were maintained ~21% O 2 in standard
growth media. (B) Graphical representation of suggested relationship between cancer-induced
cardiac atrophy and oxidative characteristics.
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Abstract: Age and obesity each contributes to cardiac hypertrophy in a unique manner as
it pertains to mitochondrial electron transport. Electron transport complexes I and IV are
implicated in defective electron transport during cardiomyopathy and contain the majority of
protein subunits that are transcribed and translated within the mitochondria. Purpose: To assess
myocardial mt-mRNA translation factors in relation to mitochondrial content and mtDNAencoded protein products using a mouse model of aged obesity and to test the necessity of mtmRNA translation initiation factor 2 (mtIF2) in maintaining oxidative capacity and the cellular
oxidation-reduction (redox) state in cardiomyocytes. Methods: C56BL/6J mice fed lean or high
fat diet were aged to either ~3 months or ~22 months and the myocardium assessed using
immunoblot and qPCR to determine differences in mitochondrial mRNA translation machinery.
Using H9c2 cardiomyocytes, mtIF2 was knocked-down and two-photon excitation fluorescence
(TPEF) of optical redox ratio (FAD/NADH + FAD), oxygen consumption, and hypoxic
resistance was tested. Results: Aged mouse hearts were larger and contained less mtIF2 protein
alongside reduced content of proteins encoded by mtDNA (CytB). Reducing the content of
mtIF2 is associated with reduced oxidative characteristics such as OXPHOS complex I and IV
content, optical redox ratio, oxygen consumption, and viability following hypoxia. Conclusion:
We present evidence of altered mt-mRNA translation during cardiac hypertrophy in aged
obesity. We build on these results by demonstrating the necessity of mtIF2 in maintaining
oxidative characteristics of cardiac muscle cells.
Keywords: Cardiac Hypertrophy; Optical redox Imaging; bioenergetics; Hypoxiareoxygenation; mitochondrial quality.
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Introduction
Aging and obesity -- by themselves -- both contribute to cardiovascular diseases (CVD)
such as congestive heart failure and coronary artery disease (8, 25); however, when combined in
aged, obese patients, the risk for cardiac event, CVD mortality and all-cause mortality is greater
than either condition alone (4, 35, 49). Each of these conditions are particularly relevant because
of the increasing prevalence of both aging and obesity in recent years (5, 33). Being both
advanced in age and obese each contributes to cardiac hypertrophy in a unique manner (6).
Counterintuitively, epidemiological data suggests that obese patients with diagnosed heart
disease have improved mortality rates compared to their age-matched, lean counterparts (1). This
‘obesity paradox’ is thought to be a result of greater circulating plasma free fatty acids
contributing to the pool of metabolic substrates in the myocardium. This reduces the contribution
of glycolysis to total ATP production and prevents the shift towards a more glycolytic phenotype
that is characteristic of heart failure (11, 15, 45). This suggests a unique set of metabolic
stressors that is placed on the myocardium of aged, obese cardiac patients.
Heart failure is characterized by a reduction in mitochondrial oxidative capacity and an
associated increase in mitochondrial production of reactive oxygen species (ROS) due to
inefficient electron transport through oxidative phosphorylation complexes (OXPHOS) (47).
Deleterious OXPHOS byproducts produced over the lifespan may contribute to mutations in
mitochondrial DNA (mtDNA) which is particularly susceptible due to its close proximity to
electron transfer, lack of dedicated repair machinery, and propagation of mutated mtDNA copies
(21, 24, 37). However, some research suggests mtDNA mutations may not result in greater
deleterious OXPHOS byproduct production nor lead to the aging phenotype (39, 50). It is, thus,
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unclear if greater ROS is a consequence of another process that alters electron transport
efficiency in the diseased myocardium.
Reductions in cardiac oxidative capacity have been explained, in part, by reduced
electron transport through complexes I and IV of the electron transport chain (ETC) (34) which
contain a majority of the subunits encoded by mtDNA (10). Alterations in mtDNA-encoded
subunit expression can alter the balance between nuclear and mitochondrial constituents of the
ETC and generate non-functional complexes (48). The process of mitochondrial-mRNA (mtmRNA) translation is responsible for synthesizing and inserting the 13 protein subunits of the
ETC that remain encoded by mtDNA (22, 42). mt-mRNA translation is governed by a discrete
set of translation machinery within the mitochondrial matrix including mitoribosomes, mttRNAs, and a specialized set of nuclear-encoded proteins to orchestrate the process (31, 32).
These proteins include mitochondrial initiation factors (mtIFs), elongation factors (mtEFs), and
translation activators that help govern each step of the mt-mRNA translation process and is
directly tied to ETC capacity and thus production of ROS in the myocardium.
Mutations in key controllers of mt-mRNA translation result in altered ETC capacity
thereby leading to greater production of ROS (42). Furthermore, we have demonstrated that gene
and protein expressions of mt-mRNA translation machinery are subject to change from
metabolic perturbations in various tissues (20, 28, 40) suggesting that mt-mRNA translation may
be dysregulated during cardiomyopathy. Previous research establishes a link between elevated
levels of ROS production and mtDNA mutations (37, 46) leading to early onset heart failure
(51), and decreases in lifespan (18, 30). One approach to mitigate oxidative stress of heart
disease may be to control the mt-mRNA translation/ETC/ROS production circuit (8); however,
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no prior connections between mt-mRNA translation machinery and oxidative capacity have been
determined.
In an effort to better understand how mt-mRNA translation machinery affects oxidative
characteristics of the myocardium, the purpose of this investigation was to assess myocardial mtmRNA translation factors in relation to mitochondrial content and mtDNA-encoded protein
products using a mouse model of aged obesity. By using an established, in vivo model of cardiac
hypertrophy, we were able to determine alterations attributable to aging, high fat diet-induced
obesity, and a combination of both conditions. Additionally, we used murine cardiomyocytes in
vitro to test the necessity of mt-mRNA translation initiation factor 2 (mtIF2) in maintaining
oxidative capacity and the cellular oxidation-reduction (redox) state in cardiomyocytes. We
demonstrate significant alterations in mt-mRNA translation associated with age- and obesityinduced cardiac hypertrophy and use a variety of approaches to show mtIF2 is required to
maintain functional characteristics of cardiomyocytes. This investigation provides novel insight
into the connection of mt-mRNA translation to ETC components for control of cardiac oxidative
capacity and has implications for ROS production, mtDNA mutation rates and aging.
Materials and Methods
Animal model of aged, obese mice
All methods were approved by the Institutional Animal Care and Use Committee at the
University of Arkansas. Thirty-two, male C57BL/6J mice were a generous gift from Rigel
Pharmaceuticals and were housed in the University of Arkansas Central Laboratory Animal
Facility. Animals were kept on a 12:12-hour light-dark cycle and given access to either normal
(NC, 17% fat, Teklad 22/5 Rodent Diet, 86140, Teklad Diets, Madison, WI)) or high-fat (HF,
60% kcals fat, D12492, Research Diets, Inc., New Brunswick, NJ) chow beginning at 3 weeks of
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age. The study consisted of four groups: young lean (YL), young obese (YO), aged lean (AL),
and aged obese (AO) (n = 8 per group). Mice that were 3-4 months and 22-24 months old were
considered young and aged, respectively. Mice were given access to water and chow ad libitum.
Following euthanasia, heart samples were snap frozen and stored at -80oC before further
analysis.
Immunoblot analysis
Protein was extracted from small fractions of muscle taken from the hearts, separated by
8% or 12% SDS-PAGE and transferred to polyvinylidene fluoride membrane as described (9,
19) alongside molecular weight ladder (BioRad #1610394). Membranes were blocked using 5%
milk in TBS (w/v) with 0.2% tween and incubated with specific primary antibodies at 4°C
overnight. Primary antibodies were specific to COX-IV (Cell Signaling Technologies, #4844),
PGC-1α (Santa Cruz Biotechnologies, sc-13067), TFAM (Cell Signaling #7495), mtIF2 (Santa
Cruz #365477), mtIF3 (Origene TA800421), mtEF-Tu (TUFM, Abcam ab67991), TACO1
(FLJ36733, Abcam ab 121688), Cyt-B (Santa Cruz 11436), ND4 (Santa Cruz #20499), VDAC
(Cell Signaling #4866), AMPK (Cell Signaling #2793), phosphorylated AMPKThr172 (Cell
Signaling #2535), Total OXPHOS Cocktail (Abcam ab110413). Using appropriate HRPconjugated or fluorescent conjugated secondary antibodies, protein antigens were visualized
within a linear range by either ECL on Protein Simple FluorChemM (Minneapolis, MN) or nearinfrared fluorescence on Odyssey Fc (LI-COR, Lincoln, NE) and analyzed using ImageStudio
Software (LI-COR). Bands were normalized to the 45kDa Actin band of PonceauS as loading
control. For each experiment, all groups were represented on each membrane and normalized to
control.
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Gene Expression Analysis
RNA isolation followed by reverse transcription real time polymerase chain reaction was
performed as previously described (20, 27, 29). Briefly, RNA was isolated using Trizol ragent
and Ambion RNA Isolation Kit (Ambion, ThermoFisher Scientific, Grand Island, NY, USA),
reverse transcription was performed using 1μg RNA and Superscript VILO cDNA synthesis kit
(11754, Invitrogen) according to manufacturer protocol. cDNA was amplified in 25μL reaction
containing TaqMan Gene Expression Mastermix and appropriate fluorescent probe for 18s
(Mm03928990), or using SYBR Green chemistry with previously described primer sets for 12S
rRNA and 16S rRNA(28). Samples were incubated at 95°C for 4 min, followed by 40 cycles of
denaturation, annealing, and extension at 95, 60, and 72°C. Fluorescence was measured at the
end of the extension step for each cycle. Cycle Threshold (Ct) was determined and the ΔCt value
calculated as the difference between Ct value and 18s Ct value. 18S Ct was not different among
experimental groups. Final quantification of gene expression was calculated using the ΔΔCt
method. Relative quantification was calculated as 2ΔΔCt.
H9c2 Culture experiments
H9c2 ventricular cardiomyocytes were purchased from ATCC (CRL-1446) and grown at
370C, 5%CO2, and 20% O2 in DMEM containing 10% FBS and 1% pen/strep and changed every
second day. When cells were ~75% confluent, 5x104 cells/well were sub-cultured in 6-well
plates for 24 hours before liposome-mediated gene transfer was performed as previously
described (29). Briefly, 1μg of shRNA-mtIF2 (sh-mtIF2; Catalog #RSH045068, Genecopeia,
Rockville, MD, USA) or a shRNA scramble control sequence (sh-con) was diluted in 50μL
reduced serum media combined with Lipofectamine 2000 (ThemoFisher Scientific). Cells were
incubated for 5 hours before rinsing and replacement with standard growth media.

128

Two-photon excitation fluorescence of endogenous NADH and FAD
Two-photon excitation fluorescence (TPEF) was used to measure endogenous
fluorescence of NADH and FAD as previously described (2). Briefly, laser excitation by MaiTai
Ti:Sapphire laser source (Spectra-Physics, Santa Clara CA) was tuned to 755nm or 860nm.
Images were acquired using a resonant-galvo scanner and GaAsP photomultipler tubes (H742240, Hamamatsu) with 460/40 nm(NADH), 525/45 nm(FAD), and 600/70 nm (Rhodamine)
filters. 10μm section of the left ventricle were cut along the short axis. Slides were imaged
(512x512 pixels, 16-bit depth, 260 μm2) and the pixel-wise FAD/(NADH+FAD) ratio
normalized to rhodamine was calculated. Multiple fields were imaged for each sample and
averaged to represent an individual biological sample. NADH and FAD image analysis was
completed using MATLAB (MathWorks, Natick, MA).
Bioenergetic flux analysis
Oxygen consumption rates (OCR) were analyzed using Seahorse XFp extracellular flux
analyzer (Agilent, Santa Clara, CA) according to manufacturer instructions and as previously
described (3). Briefly, 24 hours following shRNA transfection, cells were trypsinized, rinsed
with PBS, and 2x104 cells were seeded per well in growth medium. After 24 hours incubation,
media was removed and replaced with Seahorse Assay media containing 7 mM glucose, 2 mM
pyruvate, and 2 mM glutamine. OCR was measured prior to and following sequential addition of
1 μM oligomycin, 1 μM FCCP, and 1 μM rotenone/Antimycin A. This allowed assessment of
cellular OCR related to basal respiration and maximal uncoupled respiration. Reserve respiration
was determined as the difference between maximal and basal after normalizing to nonmitochondrial oxygen consumption.
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Hypoxic exposure and MTT viability assessment
To assess the resistance of H9c2 cells to hypoxia similar to that seen during ischemic
challenge, 48 hours following shRNA transfection, media was replaced with serum-free DMEM
and cells were placed in a dual gas controlled (Oxycycler C42, Biospherix, Parish, NY)
incubator sub-chamber. Oxygen was flushed by nitrogen and maintained at 1% O2 and 5% CO2
for 6 hours. The combination of serum-free media with a hypoxic environment was used to
simulate ischemic conditions (26). Following hypoxic exposure, 1 mM MTT (M6494,
Invitrogen) was added to cells and incubated ~20% O2 for 2 hours. The resulting formazan
crystals were solubilized by addition of 1000 μL of 350 mM SDS in 0.01% HCl and absorbance
was read at 570 nm. A separate plate was maintained at ~20% O2 to serve as 100% viability
control.
Statistical Analysis
Statistics were calculated and visualized using GraphPad Prism v6.0. For animal studies,
a 2x2 analysis of variance was used to compare conditions of age (young vs. aged) by diet (lean
vs. obese). Where significant interactions occurred, Fisher’s LSD post hoc analysis was used to
determine differences between groups. To compare shRNA-control to shRNA-mtIF2, Student’s
t-test was used. For all experiments, α was set at 0.05 and data presented are mean ± SEM.
Results
The obesity, aging, and cardiac hypertrophy phenotype
Phenotypic data regarding animal age, body weight, tibia size, and heart weights from
this animal cohort have been previously published. Overall, the high-fat diet animals were
significantly heavier than their age-matched lean counterparts. Absolute and relative to tibia
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length, heart weight showed a main effect of age (~20% greater) and diet (~20% greater) as
being significant contributors to elevated heart mass.
Mitochondrial content alterations in the myocardium during aging and obesity
To assess mitochondrial content of the heart in this animal model, we used immunoblot analysis
of the surrogate marker COX-IV as well as controllers of mitochondrial biogenesis and
replication, PGC-1α and TFAM. COX-IV protein was ~40% greater in both aged groups
compared to young (p < 0.05) with no significant effect of diet (p > 0.05; Figure 1A). PGC-1α
protein content was differentially expressed by both high-fat diet and age. YO and AL groups
showed ~2-fold and 1.5-fold greater content of PGC-1α compared to YL and AO groups (p <
0.05) while there was no difference between YL and AO groups (p > 0.05, Figure 1B). No
significant differences were found in the protein content of TFAM between any groups (p < 0.05,
Figure 1C).
Mitochondrial mRNA-translation alterations in the myocardium during aging and obesity
To understand the effects of aging and obesity on the process of mt-mRNA translation in the
myocardium, we analyzed key controllers of the mt-mRNA translation process. First, we
examined major components of the mitochondrial ribosomal subunits, mitochondrial 12S rRNA
content was ~30% lower in high fat diet groups compared to lean (p < 0.05) and ~45% lower in
aged groups compared to young (p < 0.05, Figure 2A). In the YO group, the 16S rRNA was only
~25% that of the YL control (p < 0.05). Both aged groups had ~30% lower 16S rRNA compared
to the YL controls (p < 0.05) but were not different than each other (p > 0.05, Figure 2B). High
fat diet (~25%) and aging (~40%) both showed significantly lower levels of mtIF2 protein
compared to lean and young controls, respectively (p < 0.05, Figure 2C). mtIF3 protein content
was ~50% greater in AO group compared to YO and AL (p < 0.05) but when compared to YL,
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this did not reach statistical significance (p = 0.083, Figure 2D). mtEF-Tu protein content was
not different between young groups but the AL group was about 2-fold greater when compared
to AO (p < 0.05, Figure 2E). TACO1 content was ~35% lower in both high fat diet groups
compared to their lean counterparts, with no significant effect of age (p < 0.05, Figure 2F).
Mitochondria-encoded CytB protein levels were ~25% lower in high fat diet groups compared to
lean controls and ~25% lower in aged groups compared to young controls (p < 0.05, Figure 2G).
When normalized to protein levels of COX-IV to account for mitochondrial content, CytB was
~45% lower in both aged groups compared to young counterparts (p < 0.05, Figure 2H).
Genetic downregulation of mtIF2 alters oxidative capacity of cardiomyocytes
In order to assess the necessity of mtIF2, and thus limitations in mitochondrial mRNA
translation, on oxidative capacity of cardiac muscle cells, we utilized a transient knockdown
approach in vitro using H9c2 cardiomyocytes. Immunoblot analysis of sh-mtIF2 transfected cells
reveals 22% lower protein content of mtIF2 compared to sh-Con (p < 0.05; Figure 3A). COX-IV
and VDAC were used as markers of mitochondrial content with no differences found between
sh-Con and sh-mtIF2 cells (p > 0.05; Figure 3A). The ratio of phosphorylated AMPK to total
AMPK was significantly elevated by >2-fold in sh-mtIF2 cells compared to sh-Con (p < 0.05;
Figure 3A). Cyt-B and ND4 are two proteins translated by mt-mRNA translation machinery and
were found to be significantly lower in sh-mtIF2 compared to sh-Con by ~25% and ~15%,
respectively (p < 0.05; Figure 3A). OXPHOS complex assembly was assessed by analyzing
content of core proteins within each complex that are actively degraded when the complex is not
adequately assembled. Markers for complexes I and IV had ~15-20% lower protein content in
sh-mtIF2 compared to sh-Con (p < 0.05) with no differences seen between groups for markers of
complex II, III, or V (p > 0.05; Figure 3B). TPEF was used to visualize the optical
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oxidation/reduction state of the H9c2 myocytes. The ratio of FAD/(FAD + NADH) was
significantly lower in sh-mtIF2 by ~30% (p < 0.05, Figure 4 A, B). Bioenergetic analysis
revealed lower levels of basal OCR (~50%), maximal OCR (~30%), and reserve capacity
(~40%) in sh-mtIF2 cells compared to sh-Con (p < 0.05, Figure 4 C, D). Upon exposure to 1%
O2 for 6 hours, sh-mtIF2 cell viability was significantly lower (~20%) than that of control H9c2
cells (p < 0.05; Figure 5).
Discussion
This investigation highlights specific alterations in mt-mRNA translation machinery during the
pathogenesis of aging-induced and obesity-induced cardiac hypertrophy. Using a mouse model
of aged obesity that has been previously characterized, we identified a loss of mtIF2 despite
markers of greater mitochondrial content (COX-IV; Figure 2) alongside reductions in Cyt-B, a
protein encoded by the mtDNA, suggesting impaired mt-mRNA translation in aged obesity.
Furthermore, using in vitro genetic manipulation of cardiomyocytes, we identified the necessity
of mtIF2 in maintaining oxidative characteristics of cardiac muscle (Figures 3-5). These results
extend previous research on the metabolic alterations associated with aging-induced
mitochondrial irregularities (13, 14, 41, 45). Specifically, novel evidence is presented on the
contribution of mt-mRNA translation machinery to maintaining oxidative capacity in the
myocardium. These data demonstrate a clear contribution of mtIF2 to the unique
cardiomyopathy seen in aged obesity with implications on oxidative capacity, ROS production,
and mtDNA mutations – all of which have been connected to the decline in cardiac function over
time.
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Implications for mtIF2 during Cardiomyopathy
In maintaining 13 ETC-subunit encoding genes in mtDNA, dedicated machinery to transcribe
and translate each gene into a protein becomes necessary. We have assessed this machinery by
analyzing regulators of mt-mRNA translation ribosomes, initiation, elongation, and the only
known mammalian translational coactivator. From these analyses, we identified detriments in
mtIF2 and mt-rRNAs during a form of cardiomyopathy. Bacterial and eukaryotic, cytoplasmic
mRNA translation each contain three translation initiation factors; however, mammalian
mitochondria contain only two with no currently known equivalent of the initiation factor 1 (IF1) (54). Functionally, the mammalian mtIF2 appears capable of replacing both IF-1 and -2 of E.
Coli resulting from a 37 amino acid insertion from IF-1 into mammalian mtIF2 allowing mtIF2
to bind the start codon (fMet-tRNA), GDP, and the small ribosomal subunit to generate a preinitiation complex (16). This predicates mtIF2 as a primary controller of mt-mRNA translation
initiation. Heart disease has been associated with metabolic changes in the myocardium
including a decrease in electron transport through ETC complexes I and IV (34) – two
complexes that include >75% of the mtDNA-encoded proteins (32). Alterations in the expression
of mtDNA-encoded subunits through changes in mt-mRNA translation are one potential
mechanism contributing to metabolic irregularities present in cardiomyopathies. In support of
this, we present evidence that mtIF2 protein and the mitochondrial rRNAs are downregulated in
the myocardium by both aging and obesity and that this is concomitant with similar changes in
CytB protein levels (a protein encoded by mtDNA) despite greater markers of mitochondrial
content in aged hearts (Figures 1, 2). These results suggest detriments in oxidative capacity and
ETC components of the myocardium may directly result from impaired mt-mRNA translation
initiation and reductions in necessary mt-mRNA translation machinery due to insufficient levels
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of mtIF2 and mitochondrial rRNAs, respectively. Reductions in proper mt-mRNA translation
would likely trigger deficient oxidative capacity and perhaps lead to greater ROS production,
mtDNA mutation rate and mitonuclear protein imbalance leading to the mitochondrial unfolded
protein response further propagating the ETC deficits (8, 23, 36). The culmination of these
detriments, overtime, may contribute to the metabolic alterations associated with age-induced or
obesity-induced cardiac hypertrophy.
Necessity of mtIF2 for maintaining cardiac oxidative capacity
Our in vivo data suggests a potential contribution of mtIF2 towards altered metabolic
characteristics of the heart by limiting translation of mt-mRNA; therefore, we sought to more
clearly define the connection of mtIF2 to specific cardiomyocyte functional outcomes. Using
shRNA knockdown of mtIF2 in H9c2 cardiomyocytes, we present novel evidence for the
necessity of proper protein expression of mitochondrial translation initiation machinery to
maintain the oxidative characteristics of cardiac muscle. The optical redox ratio of FAD/(NADH
+ FAD) as visualized using TPEF is a non-destructive and label free method of live cell imaging
that can ascertain relative contribution of glycolysis and oxidative phosphorylation (3, 38, 52).
Using this approach, we are the first to report that reductions in protein content of mtIF2 can be
directly associated with a relative increase in glycolytic utilization compared to oxidative
phosphorylation (Figure 4). Furthermore, we demonstrate that insufficient expression of mtIF2
can reduce oxygen consumption capacity and exacerbate cardiomyocyte cell death following
hypoxic exposure in vitro (Figure 4,5). These results have clear implications for pathological
cardiac hypertrophy as seen during aging and obesity which both present with downregulated
cardiac mtIF2 protein content (Figure 2).
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mt-mRNA translation and Mitochondrial Quality Control
Traditional views of mitochondrial quality control encompass the processes of mitochondrial
biogenesis, mitophagy, and mitochondrial dynamics (53). Recent published evidence has
established other cellular processes and their importance for appropriate mitochondrial oxidative
metabolism including the mitochondrial unfolded protein response (25), mitochondrial
supercomplex formation (17), and mitochondrial mRNA translation (28, 44). Each of these
cellular pathways contributes to the overall function and efficiency of the ETC in producing
sufficient ATP without deleterious ROS production or a resulting increase in mtDNA mutation
rate. Published literature predicates mitochondrial metabolism in combating the deleterious
effects of aging on the heart (8) but these results, alongside other reports, suggest that
maintenance of mt-mRNA translation machinery, specifically mtIF2, directly contributes to
mitochondrial oxidative quality (7, 8, 48). Mitochondrial oxidative capacity should be a primary
target to combat the deleterious effects of acquired cardiomyopathies including aged obesityinduced cardiac hypertrophy and this should be accomplished through the appropriate quality
control mechanisms including mt-mRNA translation. Further research should aim to directly
connect mitochondrial translational outcomes to the rates of mtDNA mutation and subsequent
ROS production.
Conclusion
In summary, we present evidence of altered mt-mRNA translation during age-induced and high
fat diet-induced cardiac hypertrophy. We build on these results by demonstrating the necessity of
mtIF2 in maintaining the redox state and oxidative capacity of cardiac muscle cells. With aging
and obesity each contributing to heart disease in a unique manner, the contribution of each
towards metabolic cardiomyopathy must be made clear. Further research should focus on the
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mitigating effects mtIF2 overexpression may have on cardiac mitochondrial function (oxidative
capacity, ROS, mtDNA mutations) and how this may contribute to increased lifespan or reduced
risk for cardiovascular event.
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Figure 1. Effects of Aging and Obesity on Cardiac Mitochondrial Content. Immunoblot analysis
of mitochondrial content marker COX-IV (A) and controllers of mitochondrial biogenesis (PGC1α; B) and replication/transcription (TFAM, C). (D) Sample immunoblot images. Each group
was represented equally across membranes and normalized across membranes using an internal
control. * indicates p < 0.05 between groups connected by horizontal bar.
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Figure 2. Effects of Aging and Obesity on Cardiac Mitochondrial mRNA translation. RT-qPCR
analysis of mitochondrial rRNA content (A,B). (C-F) Immunoblot analysis of protein content of
machinery involved in mitochondrial mRNA translation and CytB -- a protein encoded by
mtDNA normalized to PonceauS (G) or mitochondrial content (H). (D) Sample immunoblot
images. Each group was represented equally across membranes and normalized across
membranes using an internal control. * indicates p < 0.05 between groups connected by
horizontal bar.
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Figure 3. shRNA-mtIF2 alters protein content of markers of mitochondrial metabolism. (A)
Immunoblot analysis of mtIF2, COX-IV, VDAC, phosphorylation ratio of AMPK, Cyt-B and
ND4 in shRNA-Con and shRNA-mtIF2 transfected H9c2 cardiomyocytes and (B)
mitochondrial OXPHOS complexes. (C) Sample immunoblot images. Analyses were performed
in triplicate with multiple independent experiments. * indicates p < 0.05.

144

Figure 4. shRNA-mtIF2 alter oxidation/reduction state in H9c2 Cardiomyocytes. (A,B) TPEF of
optical redox ratio [FAD/(FAD+NADH)] in H9c2 cardiomyocytes transfected with either
shRNA-Control or shRNA-mtIF2. Bioenergetic flux analysis of H9c2 cells over time (C) and
resulting relative OCR as a proportion of the control basal rate. Analyses were performed in
triplicate with multiple independent experiments. * indicates p < 0.05.
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Figure 5. (A) mtIF2 contributes to cardiomyocyte hypoxic resistance. MTT assay of cell
viability conducted after 6 hours of incubation at 1% O 2 in H9c2 cardiomyocytes transfected
with either sh-Con or sh-mtIF2. Analyses were performed in triplicate with multiple independent
experiments. * indicates p < 0.05. (B) Conceptual illustration of results.
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Chapter 5 – Discussion
This series of experiments has established the importance of the mt-mRNA translation
machinery in maintaining mitochondrial oxidative capacity in the myocardium. The specific
aims outlined within this dissertation have determined 1) mt-mRNA translation is altered in an
aging- and obesity-induced model of cardiac hypertrophy, 2) mt-mRNA translation is
dysregulated in the unique cardiac atrophic state seen in advanced cancer and 3) mt-mRNA
translation initiation through mtIF2 is required to maintain cardiac oxidative characteristics. We
have accomplished these experiments through a combination of unique in vivo mouse models of
heart disease followed by specific in vitro genetic approaches targeting mt-mRNA translation
machinery using a variety of biochemical and functional assessments. The implications of these
experiments extend areas of cardiometabolic disease, cardio-oncology, and the basic science of
mitochondrial quality control mechanisms to maintain oxidative characteristics of the most
mitochondria-dense tissue within the human body.
Until now, the primary focus of research into mitochondrial therapeutics to combat heart
disease has been enhancing lipid utilization and improving mitochondrial quality control
pathways (7, 22). The goal in targeting mitochondrial quality control pathways is to optimize the
pool of mitochondria by eliminating non-functional organelles (mitophagy) (21) and optimizing
the interconnectedness of the mitochondrial reticulum (dynamics) (4). Other attempts to promote
mitochondrial biogenesis through overexpression of the master regulator PGC-1α have been
limited because of a type of ceiling reached on mitochondrial content in the already extremely
oxidative cardiac muscle (3, 11). These studies have suggested the insufficiency of approaches
targeted towards canonical mitochondrial quality control mechanisms. The results of our
investigations into mt-mRNA translation demonstrate the paramount importance of maintaining
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the pool of mitochondrial OXPHOS subunits coded by mtDNA to maintain the integrity of the
ETC. It should, therefore, be noted that mt-mRNA translation is now implicated as a key
component of proper and sufficient mitochondrial oxidative quality in order to produce ATP
required for oxidative muscle contraction of the heart.
The cumulative results of these investigations have further supported the potential of
mitochondrial oxidative capacity as a therapeutic target in cardiac myopathies. Specifically, we
have extended upon previous evidence by demonstrating a specific area of cardiac mitochondrial
characteristics responsible for poor metabolism during heart disease. We present novel evidence
that the obesity paradox that is seen during aged obesity-induced cardiac hypertrophy could be
counteracted by mitigating detrimental mt-mRNA translation initiation to improve functional
characteristics (1, 15). Furthermore, we are the first to present evidence of mitochondrial
oxidative alterations in the unique form cancer-induced cardiac atrophy – a more prevalent form
of heart disease as efficacy of cancer treatments are improving (16). Many avenues of targeting
mitochondrial therapeutics to treat cardiovascular disease have been anticipated but few have
focused on the formation of mtDNA-encoded proteins in the development of ETC complexes for
OXPHOS efficiency. A potential deterioration in the abundance of OXPHOS proteins encoded
by mtDNA relative to total volume of the mitochondria has not been explored during heart
disease.
The relative contribution of mitochondrial content to total mass of contractile tissue in
striated muscle is dysregulated during metabolic disease states such as insulin resistance or
obesity in both skeletal and cardiac muscles (8–10, 12). Here, we present with markers of
mitochondrial content in the heart indicating this condition is similar within the heart during
various disease states. By utilizing multiple disease models with a common downregulation of
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mtIF2 and genetic approaches to reduce expression of mtIF2 in cardiac musculature, we
demonstrate that reduction in mt-mRNA translation are seen concomitant with an increase in
markers of mitochondrial content. This suggests that an elevation in total mitochondrial content
with insufficient OXPHOS machinery to match metabolic demand. It stands to reason that a
reduction in mt-mRNA translation results in fewer ETC complexes and a reduction in the Δψ of
the mitochondria limiting ATP production at complex V. Though not yet supported by
experimental evidence, it is possible that a reduction in ATP production of the cardiac
mitochondrial pool causes a reciprocal promotion of mitochondrial network expansion to cope
with oxidative stress (5). This would mean an increase in mitochondrial content as a result of
poor oxidative phosphorylation in the pool of mitochondria at the onset of disease provides a
means to restore energy balance -- referred to in the literature as mitochondrial retrograde
signaling (5). Of course, this is contrary to traditional scientific thought wherein an increase in
mitochondrial content is a result of insufficient mitochondrial fusion and degradation of poorly
function components (9). Our results support mitochondrial turnover as a causal proponent of
greater mitochondrial content in cancer-induced cardiac metabolic perturbations. However, the
former conclusion could be supported by our results in hypertrophic cardiomyopathy and
genetically altered cardiomyocytes though further experiments would be needed to confirm
mitophagy is not a factor.
In conclusion, the research investigations presented within this dissertation are the first to
establish mitochondrial mRNA translation as a process that is dysregulated during
cardiometablic disease and as a potential therapeutic target to enhance oxidative characteristics
of the myocardium. mtIF2 presents as a key regulator for the process of mt-mRNA translation
and is necessary for maintain oxidative capacity in cardiac muscle. A disruption in the
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expression of mtDNA has deleterious effects on the assembly of OXPHOS complexes;
specifically complexes I and IV based on the number of core subunits encoded by mtDNA.
Alterations in the flow of electrons through these specific complexes has strong implications for
the production of ROS and the subsequent consequences on mtDNA integrity. Any metabolic
alterations that result in mtDNA mutations can propagate to further detriments in OXPHOS
complex assembly leading to further ROS production and even greater mtDNA mutations
causing a ‘downward spiral’ of metabolic disturbances (23). This series of events has the
potential for altering the future care of many cardiac disease states including cardiac
hypertrophy, coronary artery disease, and age-induced congestive heart failure.
Future Directions
This series of experiments has taken clear steps to improve our knowledge in a series of
cardiomyopathies; however, it leaves open many future lines of research to build upon these
findings. Primary experiments that could be used with these experimental models would be the
quantification of ROS production and mtDNA mutations and mutation rates. These experiments
would directly connect our findings to a prolonged propensity for deleterious effects on the heart.
Furthermore, these experiments have tested the necessity of mtIF2 in maintaining cardiac
oxidative capacity -- it is yet to be seen if mtIF2 is sufficient to enhance hypoxic resistance in
adult cardiac muscle. These future experiments would clearly pave the way for translational
experiments to use mtIF2 exogenous expression to mitigate deleterious effects of
cardiomyopathies. If this is extended to a mitigation of mtDNA mutation through reduction in
ROS production, it would pave the way for age mitigating therapeutic approaches.
Another area that requires future research is in characterization and mitigation of
cardiotoxic effects of therapeutic pharmaceutical interventions already implemented in a clinical
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setting (16). While multiple approaches assist in treating diseases associated with aging and
obesity (Metformin)(19) and cancer (Doxorubicin, Nivolumab)(17), the side-effects are often
deleterious to cardiac musculature. Clinical interventions are improving that have greatly
increased survival rates of metabolic diseases and cancers, but these are narrow minded and
counterintuitive if the resulting outcome is an imminent, fatal cardiovascular event. Researchers
need to clearly identify the adverse outcomes on the myocardium of interventions to treat cancer
(radiation, chemotherapy, immunocheckpoint blockade) and other age-related disorders
(hormone therapies, metabolic therapy, corticosteroid therapy, anti-dementia medications). The
side-effects of these treatments have clear negative side-effects on the myocardium and could be
contributors to greater mortality. Along these lines, a key initiative that should be the focus of
future research in medical administration and organization is to identify the concern of primary
care providers who administer these medications and if they are considerate of the complicating
effects on patients with or predisposed to cardiovascular disease. A wonderful example of the
positive outcomes possible is the rapidly progressing field of cardio-oncolgy wherein specialists
combine expertise to identify optimal treatment approaches to enhance outcomes of both
oncologists and cardiologists.
Limitations
Various limitations should be taken into account when attempting to generalize the
results presented here. A primary limitation of concern is the lack of in vivo functional cardiac
information including left ventricular ejection fraction, left ventricular internal diameter
measures and ventricular wall dimensions. These are all primary markers of cardiovascular
disease that can only be measured in a living animal and were not collected in either of the
animal studies presented here.
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For many of the findings taken from mouse diseases models, a primary concern in
applying this to a broader application is the drastically different hemodynamic and microfluidic
aspects of small animal cardiovascular system. In fact, when comparing characteristics of the
heart across dozens of mammalian species, a relationship between body weight, heart mass, and
heart rate is readily apparent (18). A smaller mammal such as a mouse may maintain a heart rate
over 800bpm while a fully grown Asian elephant’s average heart rate is ~35bpm (2). Much of
the differences relate to Frank-Startling contractile forces and outflow capacity through the aortic
vasculature (6). This significant difference in the rate of contraction can result in differences in
the metabolic characteristics of the myocardium across species. Similarly, the use of rat
cardiomyocytes for cell culture experiments must take into account the progenitor phenotype
(more glycolytic, less adult myosin content) compared to adult primary cardiac muscle cells (13,
22).
The use of TPEF to analyze redox species within tissue post mortum could be subject to
changes caused by oxidation that occurs during sample processing though previous research
suggests this is unlikely to alter data interpretation (24). There may also be some overlap in the
endogenous fluorescence signal of NADH and collagen SHG potentially confounding these
results. Likewise, NADPH and NADH species are indistinguishable using this endogenous
fluorescence approach. While NADPH may only make us ~5% of the total pool of
NADPH/NADH in a cell, it is assumed that this is included in our total measurements of NADH
(20).
Limitations that apply to the biochemical analyses must be taken into account as well.
For the Seahorse Bioenergetics analysis, it must be assumed that the combination of Antimycin
and Rotenone (combinations of Rotenone A, B and C) are sufficient to entirely block electron
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flow through OXPHOS complexes though this has not been directly, experimentally confirmed.
We were unable to determine production of ROS through MitoSOX analysis in sh-mtIF2
experiments because of overlapping fluorescent signal with the mCherry-tagged plasmid.
Additionally, measurements of mtDNA content and mtDNA mutation rates were not performed
nor were activity measurements of the various OXPHOS complexes but only the content via
immunoblot analysis. Finally, the MTT assay requires oxygen to generate formazan and is
subject to alterations from ROS. While commonly used in the literature, this could be
confounded by the hypoxia/reoxygenation required from the experimental protocols. While we
attempted to only assess effects of hypoxia on the cardiomyocytes, the cells must be returned to
normoxia (and thus reoxygenated) in order to perform MTT assay, the reoxygenation and ROS
effects must be noted.
Delimitations
For the experiments presented here, we have decided to forego certain experiments that
could be reasonably incorporated but have done so for specific reasons. We have attempted to
characterize our mouse models of heart disease by highlighting alterations that are consistent
with cardiomyopathy (HIF-1α, PGC-1α, fibrosis, altered oxidative metabolism) in an effort to
demonstrate a diseased state even without function measurements of cardiac characteristics
(echocardiographic assessment). While we could support these findings by using measures of
glycolytic metabolism (immunoblot analysis, activity assays, glycolytic bioenergetics flux
analysis), we have not performed these experiments because we feel that we can adequately
characterize the stated heart disease with the experiments already performed. Similarly, the in
vitro experiments have highlighted alterations in metabolic characteristics of cardiomyocytes
rather than mature myotubes. This was done in order to mitigate any effects of mitochondrial
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metabolism that contribute to muscle cell differentiation and because a primary characteristic of
heart disease is a transition towards this embryonic cardiac cell phenotype (14). Additionally,
while overexpression of the key mt-mRNA translation factors could improve the application of
these findings in a diseased state, we have elected to simply test the necessity of mtIF2 for
mitochondrial oxidative capacity. This was because prior to attempting to solve issues with
deficient mt-mRNA translation during cardiac disease, we sought to determine if this translation
initiation factor is required to maintain characteristics of healthy myocardium. Only then would
the importance of extrinsically enhancing the expression of mtIF2 become apparent. While many
more experimental approaches could be used to extend these results, we are confident that the
findings presented here are sufficient for interpretation of the results as discussed.
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Appendices
1. Protocols
H9c2 culture
H9c2 rat ventricular cardiomyocytes were purchased through ATCC (CRL-1446) and
cultured in DMEM containing 10% (v/v) fetal bovine serum and 1% (v/v)
penicillin/streptomycin. Cells were incubated at 37 and 5% CO2 with media was changed every
second day. Cells were grown until ~80% confluence and subcultured at desired densities for
subsequent experimental procedures.
Bioenergetics flux analysis
For cell bioenergetics flux analysis, a Seahorse XFp extracellular flux analyzer (Agilent,
Santa Clara, CA) was used. Drug cartridges were preincubated with Seahorse Assay media 24
hours prior to experimenst at 37°C in a non-CO2 incubator. 200μL of PBS was inserted into the
cartridge moats to allow adequate humidification. Cells were cultured and plated in Seahorse cell
plates at 2x104 cells/ well in 200μL of culture media. 200μL of PBS added to the cell plate moats
to allow adequate humidification. On the day of the experiment, Seahorse assay medium was
made using Seahorse XF base medium and adding 7mM glucose, 2mM sodium pyruvate, and
2mM L-glutamine then pH was adjusted to 7.36-7.40. Using this complete assay media, drugs
were reconstituted as follows: 252μL in oligomycin drug vial for a final concentration of 50μM,
288μL in FCCP drug vial for a final concentration of 50μM, and 216μL in Rotenone/antimycinA
vial for a final concentration of 25μM. From these stock drugs, 20μL of oligomycin was added to
port A of the drug cartridge (1μM final concentration), 22μL of FCCP was added to port B of
drug cartridge (1μM final concentration), and 25μL rotenone/antimycinA was added to port C
(0.5μM final concentration. This prepared drug cartridge was loaded into the Seahorse XFp
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analyzer at the start of the experiment as instructed by the machine’s GUI. The culture media for
the cells was removed and rinsed thrice with complete Seahorse assay media and left at a final
volume of 180μL/well to allow dilution to desired concentrations from drug cartridge. ~15
minutes after inserting the drug cartridge into analyzer, the hydrating plate can be removed and
the cell plate inserted according to instructions given by the machine’s GUI. Analysis will be
performed over 100 minutes and the drug cartridge and cell plate can be removed and used for
further analyses if desired.
Cell Hypoxic exposure and MTT Assay
2x104 cells/well are plated in a 96-well plate and incubated with culture media for 24
hours at 20% O2 and 5% CO2. After desired experimental intervention (transfection, drug
incubation), media was replaced with media deplete of serum and cells were placed in a dual gas
controlled incubator sub-chamber (Oxycycler C42, Biosperix, Parish, NY). Oxygen was flushed
by nitrogen and maintained at 1% O2 and 5% CO2 for 6 hours. Following the hypoxic exposure,
1mM MTT (M6494, Invitrogen) was added to cells and incubated at ~20% O 2 for 2 hours. The
resulting formazan crystals were solubilized by addition of 100μL af 350mM SDS in 0.01% HCl
on gentle shaking for 2 hours. Absorbance was read at 570nm and compared to absorbance of a
control plate incubated in normoxic conditions.
Two photon excitation fluorescence
Two-photon excitation fluorescence (TPEF) was used to measure endogenous
fluorescence of NADH, FAD, and the second harmonic generation signal of collagen (SHG).
Laser excitation by MaiTai Ti:Sapphire laser source (Spectra-Physics, Santa Clara CA) was
tuned to 755nm (NADH), 800nm (SHG), or 860nm (FAD). Images were acquired using a
resonant-galvo scanner and GaAsP photomultipler tubes (H7422-40, Hamamatsu) with
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460/40nm (NADH), 525/45nm (FAD), 400/40nm (SHG) and 600/70nm (Rhodamine) filters.
10μm section of the left ventricle were cut along the short axis. Slides were imaged (512x512
pixels, 16bit depth, 260μm2). The pixel-wise FAD/(NADH+FAD) ratio normalized to rhodamine
was calculated to determine the optical oxidation/reduction ratio. Multiple fields were imaged for
each sample and averaged to represent an individual biological sample. Image analysis was
completed using MATLAB (MathWorks, Natick, MA).
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2. MATLAB Editor Code
Redox ratio calculations in whole tissue microscopy
%Create a nice image (avgi2) by combining the FAD and NADH
%channels

% Select your highest level folder containing all the data
start_path = uigetdir('Select a folder');
cd(start_path)

% Creates a list of all NADH and FAD folders
list_755 = dir('*750*');
list_860 = dir('*860*');
list_800 = dir('*800*');

% Goes into each folder, takes the Chan B or Chan C image depending on the
% wavelength.
for i = 1:length(list_755)
redox_755 =
imread(strcat(start_path,'/',list_755(i).name,'/','ChanB_0001_0001_0001_0001.tif'));
avg_755{1,i} = mean(mean(redox_755));
redox_755=double(redox_755);
redox_images{1,i} = redox_755;
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end
for i = 1:length(list_860)
redox_860 =
imread(strcat(start_path,'/',list_860(i).name,'/','ChanC_0001_0001_0001_0001.tif'));
avg_860{1,i} = mean(mean(redox_860));
redox_860=double(redox_860);
redox_images{2,i} = redox_860;
end
for i = 1:length(list_800)
redox_800 =
imread(strcat(start_path,'/',list_800(i).name,'/','ChanA_0001_0001_0001_0001.tif'));
avg_800{1,i} = mean(mean(redox_800));
redox_800=double(redox_800);
redox_images{3,i} = redox_800;
end

%Calculate redox images
for i = 1:length(list_755)
redox_images{4,i} = redox_images{2,i}./(redox_images{2,i}+redox_images{1,i});
avg_redox{1,i} = mean(mean(redox_images{4,i}));
end

%save('AverageRedoxImage',imavgredox);
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mf=max([avg_860{1,:}]);
mn=max([avg_755{1,:}]);

%smooth images and index redox_images structure using same color
%limits for all images
for i=1:length(list_755)
h=fspecial('gaussian',[2 2],5/3);
FADfilt=imfilter(redox_images{2,i},h);
NADHfilt=imfilter(redox_images{1,i},h);
redox = redox_images{4,i};

avgi=(mean(mean(redox_images{2,i}))+mean(mean(redox_images{1,i})))/2;

%Keep this consistent for all your images. Lowering uplim will make it
%brighter
uplim=1000;%adjust these based on your image intensity values
botlim=400;%adjust until you see the pixels gone from background

avgi2=(avgi-botlim)/(uplim-botlim);
avgi2=avgi2.*(avgi2<1)+(avgi2>=1);
avgi2=avgi2.*(avgi2>=0);

%reassign redox ratio jet colors to a range of your choosing based on uplim
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%and botlim, then discretize the redox values from 1-64.
cmj=jet;

%DO NOT CHANGE THESE VALUES
uplim=1.0;
botlim=0.4;

redoxfn=(redox-botlim)/(uplim-botlim);
redoxfn=redoxfn.*(redoxfn<1)+(redoxfn>=1);
redoxfn=round(63*(redoxfn.*(redoxfn>=0)))+1;

uplim=750;
botlim=400;

SHGfn = (redox_images{3,i}-botlim)/(uplim-botlim);
SHGfn = SHGfn.*(SHGfn<1)+(SHGfn>=1);
SHGfn = round(63*(SHGfn.*(SHGfn>=0)))+1;

%assemble the redox ratio map image in increments of different redox ratio values
RYR24=zeros(size(redoxfn,1),size(redoxfn,2),3);

for j=1:64
imm=(redoxfn==j);
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RYR24(:,:,1)=RYR24(:,:,1)+cmj(j,1).*imm.*avgi2;
RYR24(:,:,2)=RYR24(:,:,2)+cmj(j,2).*imm.*avgi2;
RYR24(:,:,3)=RYR24(:,:,3)+cmj(j,3).*imm.*avgi2;
end
redox_images{5,i} = RYR24;
end
%Save the image structure
save('images_matrices.mat','redox_images')

%Export matrix of values to excel with row1-4(NADH, 2HG, FAD, redox) and
%row as the transposed averaged for each variable
Excel_summary = [avg_755; avg_800; avg_860; avg_redox];
%Excel_summary{5,1} = mean([avg_755{1,:}]);
%Excel_summary{5,2} = mean([avg_800{1,:}]);
%Excel_summary{5,3} = mean([avg_860{1,:}]);
%Excel_summary{5,4} = mean([avg_redox{1,:}]);
excel_summary = cell2mat(Excel_summary);
xlswrite('excel_summary',excel_summary);

%Display redox image and filtered FAD and NADH images side by side
figure;imagesc(redox_images{3,1}); colormap(gray);
%subplot (1,3,1), imagesc(redox_images{5,2});colormap(jet); axis square; title 'redox';
%subplot (1,3,2), imagesc(redox_images{2,2});colormap(gray); axis square; title 'FAD';
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%subplot (1,3,3), imagesc(redox_images{1,2});colormap(gray); axis square; title 'NADH';

Redox ratio analysis in culture cells
% Select your highest level folder containing all the data
start_path = uigetdir('Select a folder');
cd(start_path)

% Creates a list of all NADH and FAD folders
list_755 = dir('*750*');
list_860 = dir('*860*');

% Parse out the folder names so data can be divided up correctly. This code
% segment looks for the first part of the filename before the 755 or 860
% in the filename

celllabel = cell(1,length(list_755));
for i = 1:length(list_755)
underscore_id(i,:) = strfind(list_755(i).name,'_');
celllabel{i} = list_755(i).name(1:underscore_id(i,2)-1);
end
clabel = unique(celllabel);
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% Goes into each folder, takes the Chan B or Chan C image depending on the
% wavelength. Based on the 755 folder, creates 7 ROIs - the first one
% always corresponds to the background and the next six selections are
% cells. Repeat this for all folders. Once you complete 1 folder, the image
% for the next folder pops up immediately.
roi_755 = cell(1,length(list_755));
roi_860 = cell(1,length(list_860));
for i = 1:length(list_755)
redox_755 =
imread(strcat(start_path,'/',list_755(i).name,'/','ChanB_0001_0001_0001_0001.tif'));
roi_755{1,i} = kmultiroi(redox_755,3);
redox_860 =
imread(strcat(start_path,'/',list_860(i).name,'/','ChanC_0001_0001_0001_0001.tif'));
roi_860{1,i} = kroistack(redox_860, roi_755{1,i});
close all
end
save 'analyzed_images.mat' roi_755 roi_860
%%
% Based on the initial filename groups we created, collects mean
% fluorescence values from all plates that belong to the same experimental
% group.
k = 1;
c = 1;

167

redox_values = struct('mean_755',[],'mean_860',[]);
for i1 = 1:length(list_755)
%if (~strcmp(list_755(i1).name(1:underscore_id(i1,2)-1),clabel{k}))
% k = k+1;
% c = 1;
% redox_values(k).mean_755 = [];
% redox_values(k).mean_860 = [];
%end
redox_values.mean_755 = cat(2,redox_values.mean_755,roi_755{i1}.mean(2:6)roi_755{i1}.mean(1));
redox_values.mean_860 = cat(2,redox_values.mean_860,roi_860{i1}.mean(2:6)roi_860{i1}.mean(1));
redox_values(c).cellplate = celllabel{i1};
redox_755 =
imread(strcat(start_path,'/',list_755(i1).name,'/','ChanB_0001_0001_0001_0001.tif'));
redox_values.img_755{c} = redox_755;
redox_860 =
imread(strcat(start_path,'/',list_860(i1).name,'/','ChanC_0001_0001_0001_0001.tif'));
redox_values.img_860{c} = redox_860;
c = c + 1;
end
%%
for k = 1:length(clabel)
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redox_values(k).redox_ratio = redox_values(k).mean_860./(redox_values(k).mean_755 +
redox_values(k).mean_860);
end
save 'analyzed_data.mat' redox_values

Redox image generation to display for publications

sampleid = 2;
load analyzed_data.mat
NADH = double(redox_values.img_755{1, sampleid});
FAD = double(redox_values.img_860{1, sampleid});
redox = FAD./(FAD+NADH);
mf=max(FAD(:));
mn=max(NADH(:));

%h=fspecial('gaussian',[1 1],5/3);
%FADfilt=imfilter(FAD,h);
%NADHfilt=imfilter(NADH,h);
%redox = imfilter(redox,h);

avgi=(FAD+NADH)/2;

%Keep this consistent for all your images. Lowering uplim will make it
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%brighter
uplim=100;%adjust these based on your image intensity values
botlim=20;%adjust until you see the pixels gone from background

avgi2=(avgi-botlim)/(uplim-botlim);
avgi2=avgi2.*(avgi2<1)+(avgi2>=1);
avgi2=avgi2.*(avgi2>=0);

%reassign redox ratio jet colors to a range of your choosing based on uplim
%and botlim, then discretize the redox values from 1-64.
cmj=jet;

%DO NOT CHANGE THESE VALUES
uplim=1;
botlim=0;

redoxfn=(redox-botlim)/(uplim-botlim);
redoxfn=redoxfn.*(redoxfn<1)+(redoxfn>=1);
redoxfn=round(63*(redoxfn.*(redoxfn>=0)))+1;

%assemble the redox ratio map image in increments of different redox ratio values
RYR24=zeros(size(redoxfn,1),size(redoxfn,2),3);
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for j=1:64
imm=(redoxfn==j);
RYR24(:,:,1)=RYR24(:,:,1)+cmj(j,1).*imm.*avgi2;
RYR24(:,:,2)=RYR24(:,:,2)+cmj(j,2).*imm.*avgi2;
RYR24(:,:,3)=RYR24(:,:,3)+cmj(j,3).*imm.*avgi2;
end

%Display redox image and filtered FAD and NADH images side by side
figure;
subplot (1,3,1), imagesc(RYR24); axis square; title 'redox'
subplot (1,3,3), imagesc(NADHfilt);colormap(gray); axis square; title 'NADH'
subplot (1,3,2), imagesc(FADfilt);colormap(gray); axis square; title 'FAD'
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3. Ethics Committee Approval Letters
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June 9, 2017

MEMORANDUM
TO:

Dr. Nicholas P. Greene

FROM:

Ines Pinto, Biosafety Committee Chair

RE:

New Protocol

PROTOCOL #:

17034

PROTOCOL TITLE:

Cardiac Oxidation Requires Mitochondrial Translation Initiation

APPROVED PROJECT PERIOD:

Start Date June 8, 2017

Expiration Date June 7, 2020

The Institutional Biosafety Committee (IBC) has approved Protocol 17034, “Cardiac Oxidation Requires
Mitochondrial Translation Initiation”. You may begin your study after certification of the biosafety
cabinet in HPER 321K.
If modifications are made to the protocol during the study, please submit a written request to the IBC
for review and approval before initiating any changes.
The IBC appreciates your assistance and cooperation in complying with University and Federal guidelines
for research involving hazardous biological materials.
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